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ABSTRACT
TRIM5α is one of the best characterized anti-viral restriction factors and works
specifically to inhibit the lifecycle of retroviruses. Following fusion of a retrovirus with its
target cell, TRIM5α binds directly to the retroviral capsid, a proteinaceous core that
houses the viral genome. Upon capsid recognition, TRIM5α forms a hexameric lattice
around the retroviral capsid and initiates its antiviral activities, which include: (1)
inhibition of viral infection; (2) inhibition of viral reverse transcription; (3) disassembly of
the capsid; and (4), activation of innate signaling pathways. Importantly, the formation of
this assembly also activates the E3 ubiquitin ligase function of TRIM5α. Ubiquitin
modification is associated with directing substrates to particular cellular pathways. We
and others have previously shown that TRIM5α spontaneously forms assemblies known
as cytoplasmic bodies in cells, and these bodies colocalize with proteins involved in the
cellular degradative pathway of autophagy. The autophagy pathway and its association
with other TRIM proteins has been implicated in serval models of pathogen clearance,
and therefore we hypothesized that autophagy may play a critical role in the function of
TRIM5α as a retroviral restriction factor. The goal of this dissertation is to define the
molecular interactions required for the association of TRIM5 proteins with autophagy
effectors and to delineate the roles of ubiquitination and autophagy in retroviral
restriction by TRIM5α. We first assessed the contribution of the autophagy pathway to
the restriction of retroviral infection or reverse transcription by TRIM5α. We
demonstrated that, when the autophagy factors ATG5 or Beclin1 are depleted in human
x

cell lines, the restriction of N-MLV by human TRIM5α, and HIV-1 by Rhesus macaque
TRIM5α and owl monkey TRIM-Cyp is preserved. These data indicate that autophagy
machinery is not required for retroviral restriction by TRIM5 proteins. However, given
TRIM5α’s activity as a ubiquitin ligase, we wanted to further probe the ubiquitindependent steps during retroviral restriction. We generated fusion proteins in which the
catalytic domain of different deubiquitinase (DUb) enzymes, with different specificities
for polyubiquitated linkages, was fused to the N-terminal RING domain of Rhesus
macaque TRIM5α. Using these fusion proteins as tools, we assessed the role of
ubiquitination in restriction and the degree to which specific types of ubiquitination are
required for the association of TRIM5α with autophagic proteins. We determined that
K63-linked ubiquitination by TRIM5α is critical for its association with autophagosome
membranes. In the absence of K63-specific ubiquitin ligase activity, TRIM5α forms a
stable association with the capsid, allowing reverse transcription to proceed, however,
infection is still blocked. These data favor a model whereby the formation of a TRIM5α
assembly around a capsid is sufficient to inhibit infection. Further, while the ubiquitin
ligase activity of TRIM5α is needed to inhibit reverse transcription, recruitment of
autophagic effectors is not required for restriction of infection or reverse transcription.

xi

CHAPTER ONE
REVIEW OF LITERATURE
HIV-1 Pathogenesis
Despite the advent of Highly Active Anti-Retroviral Therapy (HAART), infection
with Human Immunodeficiency Virus-1 (HIV-1) continues to be a significant healthcare
burden worldwide, as 40,000 Americans and ~2 million people worldwide become
infected with this virus annually [1]. Furthermore, there are currently nearly 40 million
people worldwide living with HIV-1 infection [2], and this prevalence continues to rise as
people are living longer with HIV-1 infection due to the increasing availability of HAART
[3, 4]. Encouragingly, the number of deaths associated with HIV and Acquired
Immunodeficiency Syndrome (AIDS) has decreased in recent years [3].
HIV-1 was identified as the causative agent of AIDS in the 1980s [5-7]. The
epidemic arose from the cross-species transmission of simian immunodeficiency
viruses found in African primates to humans [8]. The lineage of HIV-1 can be traced to
four different subgroups, based on their proposed species of origin: Groups M, N, O,
which were transmitted from chimpanzees; and Group P, which was transmitted from
gorillas [3]. Group M is responsible for 48% of infections worldwide and is considered
the cause of the global epidemic [9]. A related virus, HIV-2, was transmitted to humans
from sooty mangabey monkeys, and although this virus causes similar clinical
symptoms as HIV-1, it is considered to be less pathogenic because it is less
transmissible and disease progression is slower [3, 8].
1
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HIV-1 primarily targets CD4+ T lymphocytes, although other cells bearing the
CD4 marker, including macrophages, monocytes, and dendritic cells, can also be
targets of infection [3]. HIV-1 is predominantly transmitted via sexual or percutaneous
routes, and mucosal transmission represents the major (80%) route of infection [10, 11].
A mixture of quasispecies of virus, representing defective viruses, less fit viruses, and
competent viruses, are typically present in the blood or mucosal sites [12]. However, in
most cases, a single virus is responsible for transmission and productive infection, and
this virus is known as the Transmitted Founder virus [8, 12, 13]. Early replication of the
Transmitted Founder virus is associated with an induction of cytokines and chemokines
and the opportunity for the virus to infect more cells. CD8+ T cells are critical during the
early stages of infection, as they kill infected cells and facilitate other arms of the innate
and adaptive immune response [14]. Unfortunately, the development of the adaptive
immune response is sometimes associated with the mutation of epitopes, such as in the
viral envelope glycoprotein, which drives immune escape [14]. Approximately 20% of
infected individuals are able to produce broadly neutralizing antibodies that are able to
neutralize a number of HIV-1 subtypes. In infected individuals, however, these
antibodies do not lead to clearance, but rather act as drivers of escape mutations [15].
Furthermore, over time, many individuals experience a progressive loss of function of
HIV-1 specific CD8+ T cells, termed exhaustion [16]. Exhaustion is associated with a
loss of effector function and the expression of one or several inhibitory receptors,
particularly PD-1, on the cell surface [16].
Clinically, HIV-1 infection is associated with a loss of CD4+ T cells that occurs as
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a result of toxicity of infection or the immune response [17]. If infection is left untreated,
the loss of CD4+ T cells is associated with the development of opportunistic infections
and significant mortality [3]. However, regardless of treatment status, HIV-1 infection is
also associated with inflammation and general immune activation. This activation is
thought to be driven by activation of plasmacytoid dendritic cells, which produce copious
amounts of type I IFN [18]. Importantly, this heightened inflammation contributes to a
number of HIV-related complications and comorbidities, including cardiovascular
disease, cancer, neurological disease, and liver disease [3].
Latency
Despite the success of antiretroviral therapy in suppressing viral loads, the virus
almost universally rebounds after treatment interruption [3]. As a result, HIV-1 infected
individuals are generally required to remain under therapy for life in order to maintain
low viral loads and avoid the adverse sequelae associated with continued viral
replication. One of the perplexing questions in the field, and the major burden to a cure,
is determining where and how the virus remains latent during the treatment phase. This
latent reservoir is the subject of significant ongoing research. Latency in the HIV field
refers to the integration of virus’s DNA into a host’s DNA without the production of virus
[3]. The precise identity of cells forming the latent reservoir is still under debate, with
studies implicating resting, memory, and naïve T cells as potentially composing the
reservoir [19-21]. Several hypotheses have been suggested to explain the
establishment of the latent reservoir, and these hypotheses largely focus on events or
conditions that keep the virus in a transcriptionally silent state, such as integration of the
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viral DNA into transcriptionally inactive chromatin; epigenetic control of the HIV-1
promoter; the absence of transcription factors, such as NFκB, which drive the
expression of viral genes; or low expression of the viral protein Tat, which is needed for
efficient transcription of the viral genome [3, 8, 22]. Furthermore, latently infected cells
are known to persist long term and are thus a critical barrier to a cure.
Therefore, there is significant research in the field to identify methods of
eradicating the latent reservoir. One of the prevailing strategies involves activating the
cells to allow for transcriptionally silent viruses to become expressed (“Shock”) and
subsequently be targeted by antiretroviral drugs or immune responses (“Kill”) [3, 8]. To
date, many studies have investigated drugs that are able to reactivate the expression of
latent viruses, including chromatin remodeling agents and NFκB activators [3].
However, there is limited data supporting the ability of these reactivation efforts to
reverse latency in vivo [3, 8].
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Figure 1. The Clinical Course of HIV-1 Infection. The course of HIV-1 infection can
be divided into acute and chronic stages. The acute phase is associated with a high
viral load in the blood and the dissemination of the virus to different sites in the body, as
well as a decline in CD4+ T cell numbers. Over time, the chronic phase of infection
develops and is associated with the development of viral escape mutants and increased
pathological sequelae affecting multiple organ systems. Over time, AIDS develops as
the CD4+ T cell count is further depleted. The introduction of HAART therapy can
forestall many of the complications associated with late stages of disease, though the
virus remains present in latently infected cells. Reprinted with permission from [23].
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Figure 2. The Structure of HIV-1. Depicted here is the structure of the mature HIV-1
virion. HIV is an enveloped RNA virus. The viral envelope, derived from the host cells, is
studded with viral Env glycoproteins, which facilitate fusion to the target cell. Encased
within the envelope is the core. The core consists of the capsid, a proteinaceous conical
structure housing the viral genomic RNA and viral proteins, such as integrase, reverse
transcriptase, and viral accessory proteins. Reprinted with permission from [24].

7

Figure 3. The Life Cycle of HIV-1. Upon fusion, HIV-1 undergoes reverse transcription
of its RNA genome into DNA, uncoating of the capsid, and trafficking to the nucleus,
where it integrates into the host genome. HIV-1 RNA, consisting of genomic RNA and
messenger RNA, is transcribed and exported to the cytoplasm, where they can be
utilized in the synthesis of viral proteins and the generation of the next generation of
virions. Many of these steps can be inhibited by cellular proteins knowns as restriction
factors (yellow boxes). However, these restriction factors in turn can be antagonized by
viral proteins (blue circles). Reprinted with permission from [25].

HIV-1 Lifecycle
The lifecycle of HIV-1 (Figures 2 and 3) begins with the binding of the virus’s
envelope glycoprotein, gp120, to the CD4 receptor and coreceptors, such as the
chemokine receptors CXCR4 or CCR5, on target cells [26]. Subsequently, the virus
fuses with the host cell, and the viral capsid enters into the target cytoplasm. The capsid
is a proteinaceous conical core containing the viral genome and viral proteins, such as
integrase, reverse transcriptase, and viral accessory proteins (Figure 2). The term
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capsid refers to the cone-shaped unit composed of individual CA monomers, while the
core refers to the capsid structure along with its associated genome and viral proteins
[27]. Upon entry, the capsid engages the cellular microtubule network to move through
the cell and traffic toward the nucleus [27, 28].
During the core’s movement through the cytoplasm, the single-stranded RNA
genome of HIV-1 is converted into double-stranded DNA via the enzyme reverse
transcriptase within the core [29]. Reverse transcription initiates a process known as
uncoating, whereby the capsid undergoes a regulated process of disassembly or loss of
integrity, though the details of this are under considerable debate [27, 30-32].
Importantly, some amount of CA remains associated with the reverse-transcribed
genome (known at the Pre-Integration Complex, or PIC), as numerous studies have
identified host cellular factors that bind to the capsid and that are critical for trafficking of
the PIC across the Nuclear Pore Complex (NPC) and protection of the genome from
cytoplasmic sensors [27, 33, 34]. However, the capsid itself can also function as a
Pathogen Associated Molecular Pattern (PAMP) and be recognized and sensed by
cellular factors, namely TRIM5α [35]. Given these interactions with cellular factors, it
would be advantageous for the virus to mutate its capsid in order to avoid cellular
recognition. However, the capsid is considered “genetically fragile”, as mutations within
it are associated with impaired reverse transcription, trafficking, and integration, and
have been associated with innate sensing [27, 33, 34, 36, 37]. Therefore, the centrality
of the capsid to HIV-1’s life cycle and its genetic vulnerability make it an important target
for antiviral approaches, and understanding factors that bind to and target the capsid
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could give important insight into the next generation of treatment approaches to target
HIV-1 infection.
Upon reaching the nucleus, the PIC engages cellular factors at the nuclear pore
and enters into the nucleus. There are several models of how the PIC translocates into
the nucleus, concerning whether an intact core or a partially disassembled core is the
species that reaches the nuclear pore complex [27]. Nevertheless, several studies have
identified CA proteins in the nucleus, which could be relevant for optimal nuclear import
and integration site selection [27, 38, 39]. Integration of the HIV-1 reverse transcribed
DNA into the host DNA is mediated by the viral enzyme integrase, which is associated
with the PIC.
Once integrated, the virus’s genome can be transcribed to produce both viral
genomic RNA as well as mRNA [40]. Transcription relies on cellular transcription
factors, namely NFκB and NFAT, and occurs relatively inefficiently until expression of
the viral protein tat, which drives efficient viral transcription [22]. With Tat present,
several different types of viral transcripts are produced (Figure 4), and these include:
unspliced RNA, which comprises the genomic RNA and Gag or GagPol precursors
(discussed more, below); singly spliced RNA, which encodes the messages for the
Envelope glycoprotein (Env) and the accessory proteins Vif, Vpr, Vpu; or fully spliced
RNA, which encodes messages for Tat, Rev, and Nef [22].
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Figure 4. Transcription of HIV-1 RNA. Transcription of HIV-1 RNA produces several
species, due to differential splicing. These include: full length unspliced RNA (~9 kb),
which comprises the genomic RNA and Gag or GagPol precursors; singly spliced RNA
(~4 kb), which encodes the messages for the Envelope glycoprotein (Env) and the
accessory proteins Vif, Vpr, Vpu; or completely spliced RNA (~2 kb), which encodes
messages for Tat, Rev, and Nef. Reprinted with permission from [41].

Subsequently the viral protein Rev facilitates the transport of viral RNAs to the
cytoplasm where they can be used to produce viral proteins and the next generation of
virions [22, 40]. Translation of viral RNA produces several products. The Gag
polyprotein precursor, which encodes the matrix (MA), capsid (CA), nucleocapsid (NC)
and p6 domains, is produced by translation of the full-length viral RNA [40]. In addition,
a frameshift during the translation of the Gag precursor produces GagPol, which in turn
encodes MA, CA, NC, protease, reverse transcriptase, and integrase proteins [40].
Newly synthesized Gag binds to and recruits viral genomic RNA as it is exported from
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the nucleus to the cytoplasm, and in turn this complex, along with newly synthesized
envelope glycoprotein (Env), is concentrated at the plasma membrane [40].
Subsequently, the assembling virus engages members of the cellular endosomal sorting
complex required for transport (ESCRT) pathway to facilitate budding and release of the
viral particle [40]. Once the virus has been released, the protease is activated and can
cleave the Gag precursor protein into its constituent proteins [40].
During this time, the individual CA monomers assemble into the fullerene cone
structure of the capsid, in the process encapsidating the viral RNA, integrase, reverse
transcriptase, and some accessory proteins [27]. The capsid is comprised of
approximately 1,500 CA monomers that spontaneous assemble into hexamers
(predominantly) and pentamers to make up the structure of the cone [27, 42]. It is this
mature core that is released into the cytoplasm during the subsequent round of
infection.
Antiretroviral Therapy
The development of combinatorial antiretroviral therapy regimens was essential
for control of the HIV-1 epidemic and is responsible for the decreased mortality
associated with infection [43]. Currently, over 25 drugs have been developed to target
various aspects of the HIV-1 life cycle, and importantly, these drugs are utilized in
combinations to limit the potential development of drug resistance [3]. Standard
regimens include several reverse transcription inhibitors, a protease inhibitor, and an
integrase inhibitor [3]. The reverse transcription inhibitors fall into one of two classes:
nucleoside reverse transcription inhibitors (NRTI), which inhibit reverse transcription by
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acting as a “chain terminator” of DNA synthesis; and non-nucleoside reverse
transcription inhibitors (NNRTI), which bind to and inhibit the reverse transcriptase
enzyme directly [44, 45]. Significantly, the onset of therapy produces a substantial
decrease in plasma viral load, usually to levels below the limit of detection of common
laboratory tests [3]. In contrast, the rebound of CD4+ T cells is variable among patients,
and the extent of CD4+ T cell recovery, which is critical to forestall the onset of
HIV/AIDS related complications, such as the development of opportunistic infections,
could be related to the timing of initiation of treatment following acute infection [3].
Restriction Factors
Through the course of completing its life cycle, HIV-1 potentially interacts with
many different host proteins, and over the course some of these host proteins evolved
to specifically inhibit one or more steps in the viral life cycle. These factors can
collectively be termed restriction factors (Figure 3). Restriction factors were first
described in the context of defining the cellular factors that protected mice from infection
by murine leukemia virus, and the identification of Fv1 in the 1960s (discussed in more
detail, below) opened the door to look for cellular proteins that inhibit viral replication.
Since then, a number of specifically-anti-HIV restriction factors have been
characterized. Generally, restriction factors represent different classes of proteins and
act through different mechanisms, although they share some common characteristics.
Some common features include: inducibility by interferon; they can be antagonized by
viral proteins or accessory proteins; and they may display evidence of positive selection,
suggesting co-evolution with the targeted pathogen over time [46].

13
APOBEC3 Proteins.
Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-like 3
(APOBEC3) proteins are widely expressed cellular proteins that utilize their cytidine
deaminase activity to convert cytidine residues in RNA or DNA into uridines, which in
turn introduces mutations in the resulting sequence [46]. APOBEC3 proteins are
particularly deleterious to HIV-1 because the APOBEC3 proteins can be packaged into
assembled virions. Upon fusion and release of the core into the cytoplasm, APOBEC3
proteins can promote the development of mutations in the newly reverse-transcribing
DNA [47-50]. This hypermutated DNA often severely compromises viral fitness, and as
such, the HIV-1 accessory protein Vif evolved to specifically counteract APOBEC3. Vif
acts by binding to APOBEC3 proteins and promoting their ubiquitination by a cellular
ubiquitin ligase, ultimately leading to the proteasomal degradation of APOBEC3 [51].

SAMHD1.
SAM Domain and HD Domain-Containing Protein 1 (SAMHD1) is a cytoplasmic
dNTPase that acts to regulate the pool of free dNTPs in the cytoplasm, which in turn
limits the ability of HIV-1 to reverse transcribe its genome [52-54]. Importantly, SAMHD1
can be antagonized by accessory proteins from HIV-2 or SIV, namely Vpr and Vpx [54].
However HIV-1 does not encode an antagonist to SAMHD1, and this thought to explain
the relative inability of HIV-1 to infect macrophages compared to its HIV-2 and SIV
counterparts [54], as macrophages are known to possess a much lower concentration
of cytoplasmic dNTPs available for reverse transcription compared to that found in CD4+
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T cells [55].
MxB.
Myxovirus Resistance Protein B (MxB) is another interferon-inducible inhibitor of
HIV-1 infection. It interacts with the assembled capsid structure, rather than CA
monomers [56-59]. As Mx2 is a relatively newly discovered restriction factor, much is
unknown about its mechanism of action. It is thought to act after viral reverse
transcription but before integration of the viral DNA, and prevailing models propose that
Mx2 interferes with nuclear import of the PIC [60].
Tetherin.
Tetherin was identified as an interferon-inducible cellular factor that inhibits the
release of assembled virions from the producer cell [61, 62]. Tetherin is known to
anchor into the plasma membrane, however the precise mechanisms by which it block
viral release are still under debate [46]. Importantly, through the action of tetherin,
viruses are thwarted from release and are instead internalized into endosomes for
degradation [46, 62]. The HIV-1 protein Vpu antagonizes the effects of tetherin, though
its mechanism of action is also still under debate [46, 61, 62].
Capsid Binding Restriction Factors: Fv1, Ref1, and Lv1
The discovery of factors that are able to bind to the retroviral capsid began in the
1960s, as researchers investigated the factors responsible for the susceptibility of mice
to infection by Murine Leukemia Virus (MLV) [63]. Eventually, Friend virus 1 (Fv1) was
identified as the cellular factor that protects mice from MLV infection [64-67]. Two alleles
of Fv1, denoted Fv1n and Fv1b, were found to be responsible for conferring resistance
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to B-tropic MVL (B-MLV) and N-tropic MLV (N-MLV), respectively [64-67]. Sensitivity to
Fv1-mediated restriction was mapped to the capsid protein of MLV [68, 69], as the
capsids of B-MLV and N-MLV differ by a single amino acid [68]. Furthermore, restriction
of infection was found to occur after the completion of viral reverse transcription but
before integration into the host’s DNA [70]. Pre-integration Complexes (PICs) isolated
from cells expressing Fv1 were found to be competent for integration in vitro,
suggesting that Fv1 arrests PICs that are on a productive path to infection [71]. In
addition, researchers found that restriction by Fv1 could be abrogated by the addition of
increasing amounts of restriction-sensitive virus, suggesting that the activity of this
factor could be saturated [72, 73]. In 1996, the gene encoding Fv1 was identified [74,
75], and it was found that this gene was related to the Gag protein of an endogenous
retrovirus present in the mouse genome [76].
Following the discovery and characterization of Fv1, researchers sought to
identify similar cellular factors that conferred resistance to retroviral infection of nonmurine cells. In 2000, a factor known as Ref1 was identified, and it was found to protect
mammalian cells, including human cells, from infection by N-MLV but not B-MLV [77].
Intriguingly, Ref1 shared some properties with Fv1, namely, that its target mapped to
the capsid of N-MLV, and its activity could be saturated by the addition of increasing
amounts of restriction-sensitive virus [77]. However, in contrast to Fv1, Ref1 restricts
retroviral infection prior to the completion of reverse transcription [77].
Several years after the discovery of Ref1, researchers identified a similar factor,
termed Lv1, which is responsible for the restriction of lentiviral infection [78-81]. As
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Ref1, restriction by Lv1 mapped to the lentiviral capsid, could be saturated, and
occurred prior to the completion of reverse transcription [78-81]. Eventually, the
discovery of TRIM5α, a restriction factor that inhibits HIV-1 infection in Old World
Monkeys, was identified to be a species-specific variant of Lv1 and Ref1 [82-86].
TRIM Family of Proteins
The Tripartite Motif (TRIM) family is a diverse group of cellular proteins that
function in a variety of cellular pathways (Figure 5). Over 80 TRIM proteins have been
identified, and they have been implicated in functions as diverse as regulating cell cycle
progression, autophagy, innate immunity, signaling, pathogen clearance, and the
degradation of proteins [87]. The members of the TRIM family are distinguished by the
presence of the RBCC motif, consisting of: a RING domain, which acts as an E3 ligase;
one or two Bbox domains, and a Coiled-coil domain, which are important for selfassociation and higher-order assembly [87, 88]. The functions of these domains will be
discussed below.
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Figure 5. The TRIM Family of Proteins. TRIM proteins share the Tripartite Motif,
consisting of a RING, one or two Bbox, and Coiled-coil domains. The different members
of this family are distinguished by the presence of different C-terminal domains.
Reprinted with permission from [88].
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Domains of TRIM Proteins
RING Domain.
Most TRIM proteins possess an N-terminal Really Interesting New Gene (RING)
domain, which functions as an E3 ligase to catalyze the addition of ubiquitin (most
commonly), small ubiquitin-like modifier (SUMO), or Interferon-stimulated proteins of 15
kDa (ISG15) to substrates [89]. The activity of the RING domain can be regulated by
assembly mediated by the other domains, and this activity can influence the overall
function of the particular TRIM protein [87, 90].
Bbox and Coiled-coil Domains.
Both the Bbox and Coiled-coil domains of TRIM proteins are critical for their selfassociation and the formation of higher-order assemblies [90]. There are two types of
Bbox domains, type 1 and type 2, which differ in their ability to coordinate zinc ions [91].
Most TRIM proteins possess the type 2 Bbox (Bbox2), whereas others possess both
type 1 and type 2 [90]. The Coiled-coil domain is critical for dimerization among TRIM
proteins. This domain is generally helical in structure, and structural studies of several
TRIM proteins, including TRIM5α, TRIM20, TRIM25, and TRIM69, demonstrate that the
dimerization of these TRIM proteins involves the formation of an antiparallel dimer
mediated by the CC domain [87, 90].
C-terminal Domain of TRIM Proteins.
The C-terminal domains of TRIM proteins are variable and differentiate the
members of this family from one another. The C-terminal domains are important for the
binding of TRIM proteins to other factors, and they can be involved with directing TRIM
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proteins to different subcellular localizations [87, 90]. TRIM proteins are subdivided into
11 groups based on their C-terminal domains, the most common of which is the
PRYSPRY domain (also known as B30.2), which can be found in over 30 TRIM proteins
[90, 92].
Discovery of TRIM5α
For many years, scientists observed that certain primate species were naturally
resistant to infection by HIV-1, and many groups sought to identify the determinant(s)
responsible for this resistance[77, 79-81, 93]. In 2004, a screen from a cDNA library
prepared from Rhesus macaque fibroblasts identified TRIM5α as the cellular factor that
protects Old World monkey cells from infection by HIV-1 [85]. Similar to Ref1 and Lv1,
TRIM5α targets the HIV-1 capsid, its activity can be saturated, and restriction occurs
before reverse transcription [85]. Subsequent studies concluded that Ref1 and Lv1 are
species-specific variants of TRIM5α [82, 83]. Importantly, TRIM5 proteins possess the
ability to restrict retroviruses from different species (Figure 6), and different primate
orthologues of TRIM5 were shown to have variable restriction efficiency of different
retroviruses [94, 95].
While TRIM5α and Fv1 are both retroviral restriction factors, they have several
important differences in their structure and function. First, Fv1 and TRIM5α proteins are
very different at the primary sequence level, and Fv1 does not have a RING or BBox2
domain [63]. Nevertheless, both TRIM5α and Fv1 possess a Coiled-coil domain, which
facilitates multimerization, as well as a C-terminal domain responsible for binding to the
retroviral capsid [96-99]. Also, while restriction of retroviral infection is a conserved
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property between TRIM5α proteins and Fv1, the timing of this restriction occurs either
before or after reverse transcription [63].

Figure 6. Specifies Specificity of Retroviral Restriction by Different TRIM5
Proteins. TRIM5 proteins demonstrate species-specific restriction of different
retroviruses. Depicted here is the restriction efficacy of different TRIM5 proteins against
retroviruses, classified as strong restriction (++), mildly restriction (+) or no restriction (-).
Reprinted with permission from [63].
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Figure 7. Domains and Assembly of TRIM5α. (A) The domain structure of TRIM5α,
discussed below. TRIM5α forms an antiparallel dimer (putative structure in (B)). TRIM5α
further assembles into a hexagonal lattice formation, a model of which is depicted in
(C). Reprinted with permission from [100].
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TRIM5α: Domain Structure and Function
RING Domain.
TRIM5α possesses the RBCC motif characteristic of this family. The RING
domain of TRIM5α proteins functions as an E3 ubiquitin ligase. Early investigations of
the function of the RING domain were complicated by the observation that mutation of
the catalytic cysteine residue in the RING domain produced unstable or large, nonfunctional aggregates of protein [98, 101]. Nevertheless, later studies found that the
function of the RING domain is activated in the context of higher-order assembly of
TRIM5α proteins [102], and that the RING domain catalyzes the autoubiquitination of
TRIM5α itself [103], as well as the synthesis of free, unanchored polyubiquitin chains
[35, 103].
Bbox and Coiled-coil Domains.
As with other TRIM proteins, the Bbox2 and Coiled-coil domains of TRIM5α are
necessary for the formation of higher-order assemblies [104, 105]. Furthermore,
dimerization of TRIM5α is mediated by the Coiled-coil domain, which forms an
antiparallel dimer (Figure 7B) [106, 107], and is required for restriction [98, 108].
C-terminal PRYSPRY Domain of TRIM5α Proteins.
TRIM5α proteins possess a C-terminal PRYSPRY (hereafter referred to as
SPRY) domain, which confers restriction specificity for different retroviruses [109-113].
Early experiments investigating the saturation of restriction factors identified that the
retroviral capsid protein is the target of restriction factor binding. However, individual
TRIM5α proteins demonstrate low affinity for binding to individual CA monomers [114].

23
In contrast, this low affinity binding can be overcome by the multimerization of TRIM5α
proteins around the capsid, which thereby fosters a higher avidity interaction between
TRIM5α and the capsid [108, 115-117]. Furthermore, this low affinity interaction
between TRIM5α proteins and the capsid offers the advantage of allowing TRIM5α to
restrict multiple retroviruses, as well as to readily accommodate changes in the
retroviral capsid [115]. Owl monkeys express a variation of TRIM5α in which the SPRY
domain is replaced by a Cyclophilin A (Cyp) domain [118, 119], producing a restriction
factor known as TRIM-Cyp. As CypA is known to bind to the HIV-1 capsid [120], TRIMCyp remains a potent restrictor of HIV-1 infection.
The binding of TRIM5α proteins to the retroviral capsid is a critical determinant of
restriction, and several groups have identified regions in the SPRY domain, particularly
a 13-amino acid stretch in the variable loops of the SPRY domain, that are under strong
positive selection [121, 122]. This observation supports the hypothesis that TRIM5α is
constantly undergoing evolution in order to restrict retroviruses. Furthermore, although
human TRIM5α is less potent at restricting HIV-1 infection compared to Rhesus
macaque TRIM5α, it is likely that human TRIM5α evolved to restrict an ancient
retrovirus for which its specificity was better suited [121, 123]. Notably, introduction of a
single amino acid substitution at position 332 in human TRIM5α is sufficient to impart
potent anti-HIV-1 restriction capabilities to human TRIM5α [124]. This observation
supports the hypothesis that human TRIM5α is not grossly incapable of restriction of
HIV-1, and that strategies may exist to enhance the anti-HIV-1 restriction activities of
human TRIM5α.
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Higher Order Assembly of TRIM5α
With the cooperation of its Bbox2 and Coiled-coil domains, TRIM5α readily forms
higher-order assemblies structured as a hexagonal lattice (Figure 7C, 8) [115-117, 125].
This hexagonal lattice formation was observed to occur spontaneously in vitro (Figure
8), suggesting the formation of such an assembly is an “intrinsic property” of TRIM5α
proteins [115]. However, lattice formation forms much more readily in the presence of in
vitro assembled viral capsid assemblies, suggesting the capsid may act as a template
for seeding the formation of the TRIM5α lattice [115]. Furthermore, the TRIM5α lattice
matches the symmetry of the viral capsid lattice (Figure 8) [115]. Finally, formation of
the TRIM5α lattice facilitates dimerization of RING domains on neighboring TRIM5α
monomers within the lattice, and this arrangement thereby activates the E3 ligase
function of the RING domains [102]. Activation of the RING domain has important
implications for TRIM5α’s anti-retroviral functions, and these effects will be examined in
more detail below. Importantly, it is clear that assembly of the TRIM5α lattice around the
retroviral capsid is a critical aspect of downstream restriction functions.
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Figure 8. Assembly of TRIM5α around the Retroviral Capsid Lattice. (A) TRIM5α
spontaneously forms a hexagonal lattice structure in vitro on assembled CA assemblies.
(B) TRIM5α assembles a lattice around the viral capsid, matching the symmetry of the
viral capsid. Reprinted with permission from [115].

Ubiquitin and Ubiquitin Ligases
Ubiquitin is a 76-amino acid protein that can be covalently or noncovalently
attached to substrates, and this modification is often the signal to direct substrates to
particular cellular pathways [126, 127]. The addition of ubiquitin to a substrate involves
the coordinated action of several enzymes. A particular E1 enzyme, known as the
ubiquitin activating enzyme, binds to ubiquitin that can be found freely in the cell [87].
Subsequently, E2 and E3 enzymes, which are known as ubiquitin conjugating and
ligating enzymes respectively, catalyze the addition of the ubiquitin protein to a
particular lysine residue in the substrate [87]. Ubiquitin has seven internal lysines
(residues 6, 11, 27, 29, 33, 48, and 63), and these residues, along with the N-terminal
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methionine of ubiquitin, can be targets of ubiquitination themselves, thereby producing
polyubiquitin linkages [87, 128]. The polyubiquitin linkages can be anchored to a
particular protein substrate, or they can be unanchored [129, 130]. Importantly, different
polyubiquitin linkages are associated with different cellular fates. K48 and K63-linked
polyubiquitin chains are the most prevalent, representing approximately 80% of all
ubiquitin linkages observed in mammalian cells [131]. K48-linked polyubiquitin chains
are canonically associated with directing substrates to the proteasome for degradation,
while K63-linked polyubiquitin modification is associated with endosomal trafficking,
intracellular signaling, and DNA repair [126-128, 132-134]. Intriguingly, substrates
bearing K48 and K63-linked polyubiquitin chains have been shown to bind to
proteasome components with similar affinities in vitro [135], and proteins modified by
K63-linked polyubiquitin chains have been demonstrated to be proteasome targets in
vitro [136]. Nevertheless, there is little evidence that K63-linked polyubiquitination is a
signal for proteasomal degradation in vivo.
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Figure 9. Overview of Ubiquitin and Polyubiuquitin Linkages. Ubiquitin contains
seven internal lysine residues (K, shown in red in the bottom panel) that can be
modified by ubiquitin themselves, producing polyubiquitin chains. The structure and
most common function of these linkages is listed in the figure. Reprinted with
permission from [137].

Proteasomes and Proteasomal Degradation
The proteasome is one of the major cellular degradative pathways (Figure 10).
The eukaryotic proteasome is a 2.5 megadalton complex consisting of several important
domains [138]. The central part of the proteasome complex is composed of a hollow
20S core, within which resides the proteolytic enzymes that are responsible for the
degradation of protein substrates [138]. In addition, the central region of the proteasome
also contains a 19S regulatory region, which houses ubiquitin-binding receptors that
bind to ubiquitinated substrates and direct them into the degradative region of the
proteasome [135, 138]. The ubiquitin-binding receptors within the proteasome bind to
the ubiquitin tag, after which the proteasome machinery directs the substrate into the
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core, processively unfolding the substrate as it moves through the core [139, 140]. From
there, the unfolded protein is sensitive to degradation by the proteolytic enzymes
present within the 20S core [139, 140]. The ubiquitin itself is cleaved away from the
substrate via proteasome-associated deubiquitinase enzymes (DUBs) so that it can be
recycled [141].
Degradation of substrates via the proteasome is classically associated with K48linked polyubiquitination. Interestingly, several studies have reported that the ubiquitinbinding receptors present within the 19S region of the proteasome bind to both K48 and
K63-linked polyubiquitin chains with equal affinity in vitro [135, 138]. However, another
study found that the processivity of the proteasome varies based on the polyubitination
modifications on a substrate, with K48 or mixed polyubiquitination linkages promoting
greater processivity of the proteasome compared to K63-linked polyubiquitin chains
[134]. One proposed model to explain the role of ubiquitin chains in influencing
proteasomal processivity is that K48-linked polyubiquitin chains switches the
proteasome to an activated state, which facilitates substrate degradation [134].
Generally, K63-linked polyubiquitin chains are not associated with directing
substrates to the proteasome for degradation in vivo [142, 143]. Several models have
been proposed to explain why this linkage may not be preferred for proteasomal
degradation. First, cellular factors may occlude binding the of K63-linked polyubiquitin
chains to the proteasome [138]. One study found that members of the ESCRT
((Endosomal Sorting Complex Required for Transport) family of proteins binds to
proteins marked by K63-linked polyubiquitin chains and blocks their ability to bind to
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proteasomal components [138]. Second, proteasomal deubiquitinase enzymes may
cleave K63-linked polyubiquitin chains from substrates, thereby promoting their release
from the 19S region prior to degradation [138, 141]. Finally, it is possible that cellular
factors may selectively enhance the recruitment and binding of substrates marked with
K48-linked polyubiquitin chains to components of the proteasome, thereby promoting
their efficient degradation [138, 141]. One exception to this model is that K63-linked
ubiquitin modification to a substrate has been shown to, in some cases, act as a seed
for the generation of mixed-linkage K48- and K63- linked polyubiquitin chains, which in
turn can be directed to the proteasome for degradation [144].

Figure 10. Schematic of the Eukaryotic Proteasome. Ubiquitinated substrates
engage the proteasome either directly (a) or via adaptor proteins (b). Subsequently, the
proteasome degrades these substrates, and ubiquitin is recycled via proteasome
associated deubiquitinases (DUBs). Reprinted with permission from [145].
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Autophagy and TRIM Proteins
Macroautophagy (hereafter autophagy) is a conserved mechanism of
degradation of cytoplasmic substrates and can be induced by a number of stimuli,
including starvation, stress, or invasion by pathogens [146, 147]. It initiates with the de
novo formation of a double-membraned vesicle, termed the autophagosome, around a
particular substrate, such as cellular proteins, organelles, or even pathogens, and this
action, in turn, sequesters the contents from the cytoplasm [146, 147]. A number of
cellular proteins are involved in the formation of the autophagosome. Studies of
autophagy in yeast have identified at least thirty-one autophagy related proteins (Atg
proteins) as being involved in autophagosome formation and maturation [147]. In the
past, autophagy was considered to be a relatively nonselective degradative mechanism,
with the proteasome being considered the more selective cellular degradative pathway
[147]. However, emerging evidence identifies adaptor proteins, including members of
the TRIM family, may be responsible for the selective targeting of substrates to the
autophagosome for degradation [146]. One well-characterized adaptor protein is
SQSTM1/p62. p62 is known to be able to bind to the autophagosome membrane
marker LC3, and importantly, it is also able to bind to ubiquitinated proteins [147-149].
Once formed, the autophagosome is delivered to the lysosome, where degradative
enzymes within the lysosome can degrade or recycle the contents of the
autophagosome [147].
Recent studies have highlighted the importance of TRIM proteins in autophagic
clearance [150]. The proposed role of TRIMs in autophagy first involves the recognition
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of particular targets by TRIM proteins. Subsequently, the TRIM proteins may assemble
and recruit autophagy machinery to promote the formation of the autophagosome and
downstream clearance [150]. For example, TRIM20 and TRIM21 have been shown to
bind to components of the inflammasome pathway and the type I interferon response,
respectively, and subsequently, the TRIMs recruit autophagic machinery to these
targets to promote their degradation [151].
Mechanisms of Restriction by TRIM5α
Similar to Fv1, TRIM5α is able to restrict retroviral infection. However, early
studies of TRIM5α quickly identified important differences between the restriction
mechanisms of these two factors. Upon fusion of the virus with the host cell, the capsid
undergoes a regulated program of gradual or partial disassembly known as uncoating,
although the precise mechanisms of this process are still under debate [27]. However,
the consensus in the field is that reverse transcription of the viral genome is closely tied
to uncoating [27, 30-32]. Capsids that are too stable or too labile demonstrate impaired
reverse transcription and replication [36], and therefore, the precise timing of reverse
transcription and uncoating is a critical aspect of retroviral infection. Binding of TRIM5α
and its orthologues to the retroviral capsid occurs within minutes after viral fusion [152,
153]. TRIM5α readily forms a lattice structure around the retroviral capsid [115-117],
and subsequently, TRIM5α is able to promote the premature disassembly of the capsid
[154, 155]. This disassembly event was uncovered as researchers determined that
upon infection, pelletable capsids, which represent the higher-order structure of the
conical core, were unable to be recovered from cells expressing a restriction-competent
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TRIM5α orthologue [155]. In cells expressing human TRIM5α, one observes a decrease
in pelletable N-MLV capsid and a corresponding increase in soluble monomeric capsid
(CA) protein [155]. In contrast, while cells expressing Rhesus macaque TRIM5α
produced a similar decrease in pelletable HIV-1 capsid, an increase in soluble CA was
difficult to detect due to the presence of pre-existing soluble CA in cytoplasm of cells
[155]. Nevertheless, the loss of pelletable capsid was, in all cases, associated with a
block to infection, and the implication was that disassembly of the capsid is a critical
aspect of restriction by TRIM5α proteins [155].
Since then, a several groups have sought to determine the mechanism of how
TRIM5α disrupts capsids, leading to their premature disassembly. One hypothesis was
that following capsid binding, TRIM5α recruits the capsid and its associated viral
components to cellular degradative machinery, such as the proteasome or autophagy
pathways. Early investigations focused on the proteasome as having a central role in
restriction because, in the presence of proteasome inhibitors such as MG132, the block
to retroviral infection remains intact, but the block to reverse transcription is relieved
[156, 157]. The reverse transcription products that accumulate in the presence of
MG132 are competent for integration into DNA in vitro, indicating these products are on
a productive path to infection [156]. Furthermore, in the presence of MG132, TRIM5α
forms stabilized associations with capsids, and this has been observed by many groups
in biochemical and imaging-based approaches [152, 155, 158]. These observations
helped shape the hypothesis that TRIM5α could utilize the proteasome to promote the
degradation of the capsid and its associated viral components; when the proteasome is
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inhibited, the capsid is not destabilized, and reverse transcription can proceed, while the
block to infectivity, measured as gene expression from an integrated provirus, remains
[156, 157]. These data suggest that, similar to Fv1, restriction of reverse transcription is
not critical for restriction of infection by TRIM5α [156-158]. Furthermore, these data
suggest that TRIM5α has likely evolved multiple mechanisms to inhibit retroviral
infection [77, 156-158].
Nevertheless, the observation that TRIM5α forms stabilized complexes with the
capsid in the presence of proteasome inhibitors [152] suggested that the proteasome
has some role in the destabilization and/or degradation of viral components. Two
studies have observed colocalization between TRIM5α proteins and components of the
proteasome [159, 160]. To determine if this association with proteasomes had any
functional impact on TRIM5α’s restriction mechanism, one study tracked the fates of the
capsid, integrase enzyme, and viral RNA, throughout infection in the presence or
absence of MG132 [158]. The study found that during restriction, Rhesus macaque and
human TRIM5α solubilize the capsid and viral RNA of HIV-1 and N-MLV, respectively
[158]. However, in the presence of MG132, the core complex, containing the capsid,
integrase, and viral RNA, is retained, and these cores are indistinguishable from
unrestricted viral cores [158]. These studies concluded that the proteasome is required
for disruption of the core but not restriction of infection [158]. Collectively, these studies
suggest a two-step model of restriction by TRIM5α. In the first step, TRIM5α or its
orthologues binds to the retroviral capsid, and this is sufficient to block infection. In the
second step, which is sensitive to proteasome inhibitors, TRIM5α induces the
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premature disassembly of the viral capsid and prevents the accumulation of reverse
transcription products.
However, these studies raised key questions about the role of proteasomes in
capsid destabilization, as proteasomes are more associated with the degradation of
linear peptides rather than the consumption of a large complex, such as TRIM5α bound
to a capsid. As an E3 ubiquitin ligase, TRIM5α promotes both its own autoubiquitination
as well as the synthesis of unanchored K63-linked polyubiquitin chains [35, 103]. To
date, no study has identified the capsid as being a substrate for ubiquitination by
TRIM5α proteins [155, 158], however, it is possible that only a small portion of CA
monomers could be ubiquitinated, which would be difficult to resolve by Western blot
[158, 161]. However, another study found that expression of TRIM5α itself decreased in
the presence of a restriction-sensitive virus, and this reduction in expression could be
reversed in the presence of MG132 [162]. Notably, the reduction in expression of
TRIM5α proteins was associated specifically with being in the presence of a restrictionsensitive virus, as no reduction was observed in the context of an unrestricted virus
[162]. These data suggested a possible connection between the degradation of TRIM5α
proteins and their ability to restrict retroviruses. TRIM5α has a rapid turnover in cells
(approximately 50-60 min) [163], and one hypothesis was that the degradation of the
capsid is linked to TRIM5α’s turnover. However, cells expressing a RING domain
mutant of TRIM5α with a longer half-life still maintained the ability to restrict infection,
indicating that the fast turnover of TRIM5α proteins is not driving restriction of
retroviruses [163]. Therefore, although there appears to be a step in restriction (the
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inhibition of reverse transcription) that is sensitive to proteasome inhibitors, it is unclear
whether proteasomal degradation per se is necessary for capsid disassembly.
Importantly, several pieces of evidence argue against the proteasome having a
central role in capsid disassembly. First, TRIM5α proteins are known to bind to CA
monomers with low affinity [114], and therefore it is unclear how this low affinity binding
would transmit enough force to drive both TRIM5α and its bound capsid to the
proteasome for degradation. In addition, proteasomal degradation is classically
associated with K48- rather than K63-linked polyubiquitin chains, and it is therefore
unclear how TRIM5α, which has been associated with the production of K63-linked
polyubiquitin chains in vitro [103], is recruited to the proteasome for degradation.
Previous studies have also interrogated autophagy and its role in TRIM5αmediated restriction. We have previously observed that TRIM5α associates with the
autophagic adaptor protein p62/sequestosome1, and depletion of p62 by siRNA caused
a reduction in retroviral restriction in cells expressing human TRIM5α (huTRIM5α) or
Rhesus macaque TRIM5α (RhTRIM5α) [164] ; however, because the depletion of p62
also reduced the expression level of TRIM5α, we could not conclude that p62 is directly
required for the restriction of retroviruses by TRIM5α. However, two recent studies
implicated autophagy in the clearance of HIV-1 by TRIM5α, proposing that after binding
to the viral capsid, TRIM5α recruits autophagic machinery to degrade the virus within
the lysosome [146, 165]. Although this observation appears to disagree with other
studies suggesting a proteasome-dependent step in restriction, this apparent
discordance might be explained by crosstalk between autophagic and proteasomal
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pathways, which is known to occur in many contexts [166, 167], or by gross perturbation
of ubiquitin homeostasis caused by pharmacological inhibition of the proteasome.
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Figure 11. Proposed Models of Retroviral Restriction and Core Destabilization by
TRIM5α. (A) (left side) During the HIV-1 lifecycle, the core is delivered to the cytoplasm
of the target cell. The virus reverse transcribes is genome, uncoats its capsid, and
traffics to the nucleus for integration. (right side) TRIM5α exists as diffuse proteins or
aggregations called cytoplasmic bodies. During restriction, TRIM5α forms assemblies
around the retroviral capsid (B), and in turn this assembly formation could be sufficient
to inhibit infection. Alternatively, TRIM5α could engage the proteasome (C) or
autophagosome (D) to destabilize capsids, which may or may not be important to block
infection.

CHAPTER TWO
MATERIALS AND METHODS
Cells and Pharmaceuticals
Expression plasmids for yellow fluorescent protein-tagged Rhesus macaque
TRIM5α (YFP- RhTRIM5α) and hemagluttinin (HA)-tagged RhTRIM5α or TRIM-Cyp
have been described previously [168, 169]. To quantify TRIM5α accumulation, a
lentiviral plasmid (pLVX, Clontech) expressing human TRIM5α containing a C-terminal
Firefly luciferase reporter gene was created. HeLa and TE671 cell lines were obtained
from the American Type Culture Collection. THP-1 cells were obtained from the AIDS
reagent repository. Wt and ATG5-/- Mouse Embryo Fibroblasts (MEFs) were generously
provided by Noboru Mizushima (University of Tokyo). HeLa, TE671 and wt and ATG5 -/MEFs were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (HyClone, Logan) UT, USA), 100 U/ml penicillin, 100
µg/ml streptomycin, and 10 µg/ml ciprofloxacin. THP-1 cells were cultured in RPMI
medium with identical FBS and antibiotics as above. Cells were maintained in the
presence of 5% CO2 at 37°C. Bafilomycin A1 and MG132 (Cayman Chemical
Company, Ann Arbor, Michigan, USA) were used at 100 nM and 1 µg/ml, respectively.
Cyclohexamide was used at 20 µg/ml. Cyclosporine A (CsA; Sigma Aldrich) was used
at a final concentration of 2.5 µM.
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Cloning and Generation of Stable Cell Lines
Stable expression of YFP-LC3 was achieved by cloning YFP-LC3, described
previously [170], into a retroviral vector [21]. To generate stable cell lines, retrovirus was
prepared by transfecting equal amounts of VSV-G, pCigB packaging plasmid, EXN
YFP-LC3 into HEK293T cells. Viral supernatant was harvested 48 hrs post-transfection,
filtered through 0.45 µm filters (Milipore), and applied to A549 cells. 48 hrs after
transduction, G418 was added to the cells, and following selection, cells were collected
for phenotypic analysis.
Generation of deubiquitinase Rhesus-TRIM5α fusion proteins was performed as
described previously [171]. Briefly, catalytically active and inactive deubiquitinase
enzymes utilized in this study were: HSV-1 UL36 DUb (residues 15-260, [171, 172]);
AMSH-LP (residues 265-436, a kind gift from the Fukai Lab, University of Tokyo, [173]);
and OTUB1 (a kind gift from the lab of Wade Harper, (Addgene plasmid # 22551),
mutation described in [174]). Each of these DUBs was cloned, in frame, into a pLVX
Flag-Rhesus TRIM5α, in between the Flag-tag and a short linker sequence before the
start codon of Rhesus TRIM5α, using SOEing PCR. To generate stable cell lines,
lentivirus was prepared by transfecting equal amounts of VSV-G, psPAX2 (from Dr.
Didier Trono, NIH AIDS Reagent Program, Cat. # 11348) [175], and the pLVX-DUBRhesus TRIM5α constructs into HEK293T cells. Viral supernatant was harvested 48 hrs
post-transfection, filtered through 0.45 µm filters (Milipore), and applied to TE671, HeLa,
or A549 cells. 48 hrs after transduction, puromycin was added to the cells, and following
selection, cells were collected for phenotypic analysis.
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Generation of Knockout Cells Using CRISPR/Cas9 Genome Editing
Indicated knockout TE671, HeLa, and A549 cell lines were generated using
LentiCRISPRv2 (Addgene plasmid #52961), a gift from Dr. Feng Zhang [176]. Guide
sequences were generated using the CRISPR design tool at http://www.crispr.mit.edu
or were taken from available guide sequences from the Genome-scale CRISPR
knockout (GeCKO2) library [176]. The following oligos were annealed and cloned into
LentiCRISPRv2 (puromycin resistance) or LentiCRISPRv2-Hygromycin (which we
designed): oligo targeting ATG5: 5’- CACCGGATGGACAGTTGCACACACT-3’; oligo
targeting Beclin1: 5’- CACCGATCTGCGAGAGACACCATCC-3’; oligo targeting
p62/SQSTM1: 5’- CACCGTGAAACACGGACACTTCGGG-3’; oligo targeting control
sequence: 5’-CACCGGCACTACCAGAGCTAACTCA-3’. Lentivirus was prepared by
transfecting equal amounts of VSV-G, psPAX2 (from Dr. Didier Trono, NIH AIDS
Reagent Program, Cat. # 11348) [175, 177], and LentiCRISPRv2 (containing the guide
RNA of interest) into HEK293T cells. Viral supernatant was harvested 48 hrs posttransfection, filtered through 0.45 µm filters (Milipore), and applied to TE671, HeLa, or
A549 cells. 48 hrs after transduction, puromycin or hygromycin was added to the cells,
and following selection, cells were collected for knockout assessment by Western blot
and phenotypic analysis.
Flow Cytometry
For viral infectivity assessment by flow cytometry, equivalent numbers of
indicated cell lines were plated in 24-well plates. Dilutions of viral supernatant were
applied to the cells, after which the cells were subject to spinoculation (1200 x g, 2 hrs
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at 13°C). For experiments involving cells expressing TRIM-Cyp, cyclosporine A (final
concentration of 2.5 µM) or DMSO was added to the cells concurrently with viral
supernatant. Following spinoculation, media was subsequently changed, and after 48
hrs, the cells were harvested and fixed in a 1% formaldehyde-PBS solution for flow
cytometric analysis. Percent infectivity was determined by measuring the proportion of
GFP-positive cells in the FITC channel for 10,000 events per sample, using a FACS
Canto II flow cytometer (Becton Dickinson, San Jose, CA, USA).
Immunofluorescence Microscopy
Cells were allowed to adhere to fibronectin-treated glass coverslips and fixed
with 3.7% formaldehyde (Polysciences) in 0.1 M PIPES [piperazine-N,N'-bis(2ethanesulfonic acid)], pH 6.8. Cells were permeabilized with 0.1% saponin, 10% normal
donkey serum, 0.01% sodium azide in PBS. We used the following primary antibodies:
rabbit anti-LC3b (Sigma-Aldrich, St. Louis, MO, USA); mouse anti-LAMP2A (BD
Pharmigen, San Diego, CA, USA); rabbit anti-Flag (Sigma-Aldrich, St. Louis, MO, USA),
and mouse ant- HIV-1 p24 (Santa Cruz) . Primary antibodies were labeled with
fluorophore-conjugated donkey anti-mouse or anti-rabbit antibody (Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Images were collected
with a DeltaVision microscope (Applied Precision, Issaquah, WA, USA) equipped with a
digital camera (CoolSNAP HQ; Photometrics, Tucson, AZ, USA), using a 1.4-numerical
aperture (NA) 100x objective lens, and were deconvolved with SoftWoRx software
(Applied Precision, Issaquah, WA, USA).
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Image Analysis
20-30 Z-stack images were acquired using identical acquisition parameters.
Deconvolved images were analyzed using Imaris software (Bitplane). For analysis of
colocalization between YFP-RhTRIM5α and autophagy markers, surfaces were
generated around YFP-RhTRIM5α. Then, the maximum fluorescence intensities of
LC3b and LAMP2A within each surface were quantified. Background fluorescence
intensities were calculated and used to set LC3b and LAMP2A intensity thresholds. For
analysis of colocalization between Flag-RhTRIM5α or the deubiquitinase-fusion proteins
and YFP-LC3b and/or p24, surfaces were generated around Flag (Figure 12). Maximum
fluorescence intensities of YFP-LC3b and p24 within each surface were quantified. Both
graphing and statistics calculations were performed in Prism (Graphpad Software, Inc).
As indicated on each graph, data is presented as the mean and SEM, and significance
was determined by Student’s t-test or ANOVA, as indicated.
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Figure 12. Image Analysis Schematic. To analyze images, a particular channel of
interest is selected (B) and, and we design three dimension surfaces around the puncta
within the given channel (C, D). Then, one can determine the intensity of the other
channels within each of these surfaces in order to assess the degree of colocalization.
The surfaces are designed with an algorithm and applied to all images.
siRNA Transfections
Transcripts for several macroautophagy factors were targeted using the following
siRNAs: ATG5 (Santa Cruz Cat. No. sc-41445), Beclin1 (Santa Cruz Cat. No. sc-
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29797), p62/SQSTM1 (Santa Cruz Cat. No. sc-29679), and Control siRNA (Santa Cruz
Cat. No. sc-37007). 300,000 TE671 cells were plated in 6-well plates and were
transfected with 30 nM of the indicated siRNAs twice over a 48-hour period. The
siRNAs were transfected using Lipofectamine 2000 (Life Technologies, Cat. No.
11668027, Grand Island, NY, USA), according to manufacturer’s instructions. Wholecell lysates were prepared 72 hrs following the second transfection, as described above.
Proteins were separated via SDS-PAGE and transferred onto nitrocellulose
membranes. Membranes were probed with α-Atg5 (Novus, Cat. No NB110-53818), αBeclin1 (Cell Signaling, Cat. No. 3738), α-p62/SQSTM1 (Cell Signaling, Cat. No.
7695S), and anti-β-actin and anti-β-tubulin antibodies. Secondary antibodies conjugated
to HRP (Thermo Fisher Scientific, Waltham, MA, USA) were used where necessary,
and antibody complexes were detected using SuperSignal West Femto
chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA, USA).
Chemiluminescence was detected using a UVP EC3 imaging system (UVP LLC Upland,
CA, USA).
Virus Generation and Titering
HIV and MLV reporter virus were prepared as described previously [164]. Briefly,
HIV-1 reporter virus was produced by polyethylenimine [26] transfection of 293T cells
with 10 μg of VSV-G and 15 μg of the proviral construct R7ΔEnvGFP, in which the Nef
gene was replaced with GFP. MLV reporter virus was produced by PEI transfection of
293T cells with equal amounts of VSV-G, pCigN or pCigB packaging plasmid (for NMLV and B-MLV generation, respectively), and GFP reporter vector. Virus was
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harvested as previously described [178]. MLV was titered on CRFK cells to normalize
viral input in infectivity studies, as described previously [156]. R7ΔEnvGFP was titered
as described previously [177]
Quantitative Real-Time PCR for Viral RT Products
Quantitation of viral RT products was performed as previously described [156,
157]. Briefly, equivalent numbers of indicated cells were seeded in 12-well plates. Cells
were infected with indicated virus, and they were subsequently incubated for 18 hrs at
37°C. Genomic DNA was harvested using a DNeasy tissue kit (Qiagen, Valencia, CA,
USA) according to the manufacturer's instructions and digested with 1 unit/µl DpnI (New
England Biolabs, Ipswich, MA, USA) for 4 hrs at 37°C to remove residual plasmid DNA.
Real-time PCR was performed with SYBR green PCR reagent (Applied Biosystems,
Carlsbad, California, USA) using primers for late RT, GFP and GAPDH. Dilutions of
proviral plasmid and GAPDH (10-fold) were used to generate standard curves. Samples
were normalized to 10 ng of total cellular DNA or GAPDH standards.

CHAPTER THREE
HYPOTHESIS AND SPECIFIC AIMS
Host cell restriction factors are a class of proteins that inhibit viral replication by blocking
the ability of a virus to complete its life cycle. TRIM5α is one of the best characterized
anti-viral restriction factors. Members of the TRIM family of proteins are defined by
having a tripartite motif consisting of an N-terminal RING domain, which functions as an
E3 ubiquitin ligase; one or two B-box domains; and a Coiled-coil domain. TRIM5α is
distinguished from other members of this family by its C-terminal SPRY domain, which
allows TRIM5 proteins to directly bind to the retroviral capsid, a proteinaceous core that
houses the viral genome [85, 155]. Upon capsid recognition, the B-box and Coiled-coil
domains, which are critical for self-assembly among many TRIM family members [97,
108, 117, 179], facilitate assembly of TRIM5 to form a multimeric lattice surrounding the
viral core [115, 116, 180]. Furthermore, higher-order assembly of TRIM5 also activates
the E3 ubiquitin ligase function of the RING domain [102]. Through the formation of this
multimeric assembly, TRIM5 is able to initiate its antiviral activities, which include: (1)
inhibition of viral infection; (2) inhibition of viral reverse transcription; disassembly of the
capsid; and (4), synthesis of K63-linked ubiquitin chains that activate innate signaling
pathways and induce an "antiviral state" for the cell [35, 103, 155, 157]. While the
inhibition of viral infection by TRIM5α is well-characterized, the precise mechanism by
which TRIM5α promotes the degradation of the retroviral capsid remains unknown.
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Several groups, including our own, have determined that there is step in restriction that
is sensitive to proteasome inhibitors, as treatment with proteasome inhibitors allows
reverse transcription to proceed, though infection is still blocked, suggesting a
proteasome dependent step in the restriction process [152, 156, 157, 160, 162].
However, several recent high profile studies have implicated autophagy as having a
central role in retroviral restriction by TRIM5α [146, 165]. Thus the relationship between
the autophagic and proteasomal degradation pathways and the functions of TRIM5α
remains unresolved.
Autophagy is a conserved cellular process whereby cargoes such as proteins or
organelles are sequestered into a double-membraned vesicle and transported to the
lysosome for degradation or recycling. We and others have previously shown that
TRIM5α spontaneously forms assemblies known as cytoplasmic bodies in cells, and
these bodies colocalize with proteins involved in autophagy, including the adaptor
molecule p62/SQSTM1 and the autophagosome membrane marker LC3b [164, 181].
Furthermore, we and others have also demonstrated that the turnover of TRIM5α is
partially autophagy-dependent [146, 181]. Intriguingly, autophagy has also been
implicated in pathogen clearance. For example, a recent study described how cells
employ autophagy to clear Salmonella infection by tagging the invasive bacteria with
ubiquitin [182, 183]. These ubiquitinated bacteria are then recognized by p62/SQSTM1
and directed to autophagosomes for degradation [182, 183]. Similarly, another recent
study highlighted how infection with certain RNA viruses triggers the activation of
TRIM23, which in turn activates p62/SQSTM1 and promotes the induction of autophagy
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[160, 184]. Taken together, these observations suggest that the autophagic pathway
may play a critical role in the function of TRIM5α as a restriction factor. The goal of this
proposal is to define the molecular interactions required for the association of TRIM5
proteins with autophagy effectors and to delineate the roles of ubiquitination and
autophagy in TRIM5α restriction.
Aim 1: Determine if TRIM5 proteins require autophagy effectors for the restriction
of retroviral infection and reverse transcription. To test the requirement of
autophagy in restriction, we examined the ability of TRIM5α to restrict retroviral infection
in cells depleted of autophagic mediators ATG5, Beclin1, and p62. In all cases,
restriction of retroviral infection and reverse transcription by human TRIM5α, Rhesus
macaque TRIM5α, and owl monkey TRIM-Cyp remained potent in cells depleted of
these autophagic effectors by siRNA knockdown or CRISPR/Cas9 genome editing
[181].
Aim 2: Determine if the ubiquitin ligase activity of TRIM5α is required for its
association with autophagy effectors and its ability to restrict retroviral infection
and reverse transcription. We generated fusion proteins in which the catalytic domain
of different deubiquitinase (DUb) enzymes, with different specificities for
polyubiquitinated linkages, was fused to the N-terminal RING domain of Rhesus
TRIM5α. Using these fusion proteins as tools, we sought to assess the role of
ubiquitination in: (A) the restriction of infection and reverse transcription; (B)
destabilization of the capsid core; and (C) the degree to which specific types of
ubiquitination are required for the association of TRIM5α with autophagic proteins.

CHAPTER FOUR
RESULTS
Inhibition of Autophagy Alters the Cellular Localization of Rhesus TRIM5α
A novel characteristic of the TRIM family of proteins is their intrinsic ability to form
higher order assemblies, and in the case of TRIM5α, this activity is essential for the
ability of the protein to act as a retroviral restriction factor [169]. Normally, RhTRIM5α
localizes to both small, discrete cytoplasmic puncta, termed cytoplasmic bodies [85] and
a diffuse pool of cytoplasmic protein that is capable of forming cytoplasmic bodies de
novo around individual virions [152, 168]. We previously observed that cytoplasmic
bodies of RhTRIM5α colocalize with the autophagic adaptor protein p62 [164]. In
contrast, previous studies have observed that treatment of cells stably expressing
RhTRIM5α with MG132, a proteasome inhibitor, drives the protein to form cytoplasmic
bodies that are larger in size than normal bodies [157]. Therefore, to study the effects of
autophagic or proteasomal inhibition on the cellular localization of YFP-RhTRIM5α,
HeLa cells stably expressing YFP-RhTRIM5α were treated with BafA1, which prevents
hydrogen flux through the ATPase present on lysosomal and endosomal membranes
[185], or MG132 for 18 hrs, after which the abundance of YFP-RhTRIM5α in cells was
quantified. As shown in Figure 13, inhibition of autophagy by BafA1 altered the
localization of TRIM5α, resulting in the accumulation of more numerous cytoplasmic
bodies than observed in untreated cells (Fig. 13A and C), while treatment with MG132
recapitulated previously published findings (Fig. 13B). These observations were
49

50
validated by quantitative image analysis to characterize YFP-RhTRIM5α localization in
data sets obtained from the individual treatment groups. BafA1 treatment produced a
substantial increase in the number of cytoplasmic bodies per cell (Fig. 13D), compared
to both untreated and MG132 treated cells. Therefore, BafA1 treatment alters the
subcellular localization of RhTRIM5α, resulting in more numerous cytoplasmic bodies,
consistent with these bodies being autophagosomal structures destined for clearance
via lysosomal degradation pathways.
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Figure 13. Subcellular Localization of YFP-RhTRIM5α Changes in the Presence of
BafA1 and MG132. (A-C) HeLa cells stably expressing YFP-RhTRIM5α were seeded
onto fibronectin treated coverslips for 18 hrs. Cells were left untreated or treated with
BafA1 or MG132 during this time. Cells were subsequently fixed and stained with DAPI.
Z-stack images were collected with a DeltaVision microscope equipped with a digital
camera using a 1.4-numerical aperture (NA) 100× objective lens, and were deconvolved
with SoftWoRx deconvolution software. Individual channel images were superimposed
to create the merged panels. Images of cells left untreated (A), treated with MG132 (B),
or treated with BafA1 (C) are presented. Images are representative of at least three
experiments. (D) To quantify the number of RhTRIM5α cytoplasmic bodies in each
treatment group, 20 images were taken per treatment under identical acquisition
parameters. Each image was analyzed using Imaris imaging software. The mean and
standard error of the mean [186] are highlighted in red. *, P<0.0001.
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Rhesus TRIM5α Colocalizes with Autophagic Markers LC3b and LAMP2A
following BafA1 Treatment
Our observation that treatment with BafA1 increases the accumulation of YFPRhTRIM5α suggested that TRIM5α is degraded by an autophagic pathway.
Accordingly, if YFP-RhTRIM5α is degraded by autophagy, then we would expect that
the cytoplasmic bodies of YFP-rhTRIM5α, which accumulate upon BafA1 treatment, to
colocalize with markers of autophagy. To test this hypothesis, we utilized
immunofluorescence microscopy to quantify the degree of colocalization between YFPRhTRIM5α and LC3b, a common marker of autophagosomes, and Lysosomal
Associated Membrane Protein 2A (LAMP2A) in HeLa cells. In untreated cells, a subset
of YFP-RhTRIM5α puncta was observed to colocalize with LC3b and LAMP2A (Fig.
14A and B), with approximately 30% of the YFP-rhTRIM5α cytoplasmic puncta being
positive for at least one of these markers (Fig. 14C). However, after 6 hrs of treatment
with BafA1, the colocalization of YFP-RhTRIM5α with both markers substantially
increased (Fig 14A and B), such that ~68% of puncta were positive for one of the two
markers, and approximately 35% were positive for both LC3b and LAMP2A (Fig. 14C).
These data suggest that YFP-RhTRIM5α is rapidly turned over by autophagic
degradation. When autophagy is inhibited by BafA1, YFP-RhTRIM5α that has been
targeted for degradation accumulates in compartments containing LC3b and LAMP2A.
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Figure 14. RhTRIM5α Colocalizes with the Autophagy Markers LC3b and LAMP2.
(A and B) HeLa cells stably expressing YFP-RhTRIM5α were seeded onto fibronectin
treated coverslips. Cells were left untreated or treated with BafA1 for 6 hrs. Cells were
fixed, permeabilized and costained with rabbit anti-LC3b (A) and mouse anti-LAMP2A
(B) and DAPI. Representative images of cells left untreated or treated with BafA1 are
presented. (C) To quantify the number of RhTRIM5α cytoplasmic bodies that were
positive for LC3b or LAMP2A following each treatment, 20 Z-stack images were taken
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per treatment, under identical acquisition parameters. Imaris imaging software was used
to identify YFP-RhTRIM5α puncta, and the maximum LC3b and LAMP2A staining
intensity in each surface was calculated and plotted. Percentages indicate the number
of RhTRIM5α cytoplasmic bodies that are positive for LAMP2A, LC3b, both, or neither.
Images are representative of at least three independent experiments.

Depletion of Autophagic Effectors Does Not Relieve N-MLV Restriction by Human
TRIM5α
The above studies provide evidence to suggest that YFP-RhTRIM5α is degraded by an
autophagic pathway. We next asked if the depletion of key macroautophagy effector
proteins was able to perturb TRIM5α-mediated retroviral restriction. To this end, we
assessed retroviral restriction in human TE671 cells, which endogenously express
human TRIM5α and therefore potently restrict N-tropic murine leukemia virus (N-MLV)
but are permissive to infection by B-tropic MLV (B-MLV) [84]. TE671 cells were
transfected with siRNAs targeting ATG5, Beclin1 or p62, and the infectivity of N-MLV
and B-MLV was assessed. As expected, N-MLV infection was potently inhibited
compared to B-MLV infection in TE671 cells subject to control siRNA transfection (Fig.
15B). Notably, knockdown of ATG5, Beclin1 or p62 did not relieve the restriction of NMLV infection (Fig. 15B), suggesting that these effectors of macroautophagy are not
required for the restriction of N-MLV by huTRIM5α.

55

Figure 15. Depletion of Autophagic Mediators by siRNA Does Not Affect N-MLV
Restriction by HuTRIM5α. (A) TE671 cells were transfected with siRNAs targeting
ATG5, Beclin1, or p62, or a control siRNA. Expression of the indicated proteins was
detected by Western blot 72 hrs post-transfection. (B) TE671 cells transfected with
siRNAs targeting ATG5, Beclin1, or p62, or a control siRNA were collected at 72 hrs
post-transfection. Equal numbers of siRNA-transfected cells were plated and infected
with equivalent titers of VSV-G pseudotyped N-MLV or B-MLV. Cells were harvested 48
hrs after infection and infectivity, signified by the percentage of GFP-positive cells, was
measured by flow cytometry. The data shown here is representative of three
independent experiments.
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To confirm and extend this observation, we generated TE671 cells in which the
ATG5 gene or the Beclin1 gene were disrupted using CRISPR/Cas9 genome editing
(Fig. 16C and E). Similar to our findings in cells depleted of ATG5 or Beclin1 by siRNA,
we observed no relief of TRIM5α-mediated restriction of N-MLV in TE671 cells in which
ATG5 or Beclin1 was knocked out (Fig. 16D and F).
To determine if ATG5 or Beclin1-dependent macroautophagy are required for the
restriction of reverse transcription by TRIM5α, we also measured reverse transcription
products generated by N-MLV and B-MLV in these cells. As we and others have
previously observed, reverse transcription by N-MLV was reduced, relative to reverse
transcription by B-MLV, in unmodified TE671 cells (Fig. 16G and H). Importantly, the
restriction of N-MLV reverse transcription, relative to that of B-MLV, was preserved in
cells depleted of ATG5 or Beclin1 (Fig. 16G and H). These data demonstrate that
perturbation of macroautophagy does not abrogate restriction of retroviral infection or
reverse transcription by endogenously expressed huTRIM5α.
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Figure 16. Depletion of Autophagic Mediators by CRISPR/Cas9 Genome Editing
Does Not Affect N-MLV Restriction by HuTRIM5α. TE671 cells were depleted of
ATG5 (C) or Beclin1 (E), using CRISPR/Cas9 genome editing, and protein expression
of ATG5 in wild-type and knockout cells was confirmed by Western blot. Infectivity of
VSV-G pseudotyped N-MLV or B-MLV in wild-type or ATG5 (D) or Beclin1 (F) knockout
TE671 cells was assayed. The data shown here is representative of three independent
experiments. Wild-type or ATG5 (G) or Beclin1 (H) knockout TE671 cells were infected
with equivalent titers of VSV-G pseudotyped N-MLV or B-MLV, and viral reverse
transcription products were measured. Three independent experiments were
conducted, and the amount of viral DNA detected in each experiment was normalized to
the wild-type untransduced sample infected with B-MLV of that experiment. Error bars
represent the standard deviation of the relative number of viral DNA products detected
across three independent experiments.
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Depletion of Autophagic Effectors Does Not Relieve HIV-1 Restriction by Rhesus
TRIM5α or Owl Monkey TRIM-Cyp
We next assessed if autophagic adaptors are also required for the restriction of HIV-1
by RhTRIM5α and owl monkey TRIM-Cyp. We generated HeLa cell lines in which ATG5
or Beclin1 were disrupted by CRISPR-Cas9 genome editing (Fig. 17A and C and 18A).
When challenged with HIV-1, we observed extensive infection in wild-type HeLa cells
and in HeLa cells depleted of ATG5 or Beclin1 (Fig. 17B and D). In contrast, when wildtype and ATG5 or Beclin1-depleted HeLa cells were transduced to stably express
RhTRIM5α, these cells potently restricted HIV-1 infection relative to their untransduced
counterparts (Fig. 17B and D). Analogous results were obtained in ATG5 knockout
mouse embryonic fibroblasts (not shown).
We next examined the ability of RhTRIM5α to inhibit the formation of HIV-1
reverse transcription products in cells depleted of macroautophagy factors. In
untransduced ATG5 and Beclin1 knockout HeLa cells, reverse transcription was
reduced relative to unmodified HeLa cells, consistent with the reduction in infectivity
observed in these cells (Fig. 17E and F). In each case, however, potent restriction of
reverse transcription was observed in cells expressing rhTRIM5α, compared to their
untransduced counterparts.
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Figure 17. Depletion of Autophagic Mediators Does Not Affect the Restriction of
HIV-1 by RhTRIM5α. HeLa cells depleted of ATG5 (A) or Beclin1 (C) by CRISPR/Cas9
genome editing were transduced to stably express HA-tagged rhTRIM5α (or left
untransduced). Wild-type, ATG5 (B), or Beclin1 (D) knockout HeLa cells, either with or
without exogenous RhTRIM5α expression, were infected with a VSV-G pseudotyped
HIV-1 reporter virus, and infectivity was measured by flow cytometry. The data shown
here is representative of three independent experiments. (E) Wild-type, ATG5 (E), or
Beclin1 (F) knockout HeLa cells, either with or without exogenous RhTRIM5α
expression, were infected with equal titers of VSV-G pseudotyped HIV-1, and viral
reverse transcription products were measured by quantitative PCR. For each sample,
viral DNA, as measured by the number of GFP reporter copies detected, was
normalized to the amount of GAPDH observed in parallel samples. Three independent
experiments were conducted, and the amount of viral DNA detected in each experiment
was normalized to the wild-type untransduced sample of that experiment. Error bars
represent the standard deviation of the relative number of viral DNA products detected
across three independent experiments.
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Furthermore, we observed similar restriction in wild-type and ATG5 or Beclin1
knockout HeLa cells stably expressing owl monkey TRIM-Cyp, compared to
untransduced cells (Fig. 18B). Notably, relief of restriction by TRIM-Cyp was only
observed when infection was carried out in the presence of cyclosporine A (CsA), which
is known to inhibit the interaction of TRIM-Cyp with the capsid of HIV-1 (Fig. 18B) [119,
153]. Collectively these data reinforce that the restriction of HIV-1 infection by both
RhTRIM5α and owl monkey TRIM-Cyp is independent of macroautophagy adaptors
ATG5 and Beclin1. Furthermore, RhTRIM5α does not require ATG5 or Beclin1 to
complete restriction of HIV-1 infection or reverse transcription.
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Figure 18. Depletion of ATG5 Does Not Affect the Restriction of HIV-1 by Owl
Monkey TRIM-Cyp. (A) HeLa cells depleted of ATG5 by CRISPR/Cas9 genome editing
were transduced to stably express HA-tagged owl monkey TRIM-Cyp (or left
untransduced). (B) Wild-type or ATG5 knockout HeLa cells, either with or without
exogenous owl monkey TRIM-Cyp expression (as depicted in (A)) were infected with a
VSV-G pseudotyped HIV-1 reporter virus either in the absence or presence of
cyclosporine A (- or + CsA, respectively). Cells were harvested 48 hrs after infection and
infectivity, signified by the percentage of GFP-positive cells, was measured by flow
cytometry. The data shown here is representative of three independent experiments.
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Inhibition of Ubiquitination Produces Stable Association of TRIM5α and HIV-1 in
THP-1 and A549 Cells
Initial studies investigating the mechanism of restriction of retroviral infection by
TRIM5 proteins determined that TRIM5 causes a destabilization of the retroviral capsid
[155, 187], and early models invoked cellular degradative machinery, such as the
proteasome or autophagy pathways, as being critical mediators of this destabilization.
Previous studies identified that in the presence of the proteasome inhibitor MG132,
Rhesus TRIM5α is unable to restrict HIV-1 reverse transcription, although infection is
still inhibited [156, 157]. In addition, Rhesus TRIM5α forms stabilized complexes with
HIV-1 virions in the presence of MG132 [152, 155, 158]. Intriguingly, these complexes
stain positively for ubiquitin [152], possibly indicating a role for ubiquitin or ubiquitination
in TRIM5α’s anti-retroviral functions. As an E3 ubiquitin ligase, TRIM5α has been shown
to autoubiquitinate itself and produce unanchored K63-linked ubiquitin chains in vitro
[103]. Ubiquitination is often a marker to direct substrates to particular cellular
pathways, and we and others have observed that TRIM5α colocalizes with markers of
the autophagy pathway [146, 164, 181]. These observations suggested a possible role
for autophagy in TRIM5α’s restriction functions. However, we previously established
that restriction of retroviral infection or reverse transcription by TRIM5 proteins does not
require the autophagy effector molecules ATG5 or Beclin1 [181]. Nevertheless, it is
possible that ubiquitination contributes to other functions of TRIM5α. Therefore, our goal
was to delineate the role of ubiquitination in the anti-retroviral functionsTRIM5α and its
recruitment to autophagosomes.
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A recent study from our group determined that the E3 ubiquitin ligase function of
TRIM5α is required for its ability to destabilize retroviral capsids [171]. TRIM5α proteins
in which the Herpes Simplex Virus UL36 deubiquitinating enzyme (hereafter referred to
as DUb) fused to the N-terminal RING domain of Rhesus macaque TRIM5α (DUbRhTRIM5α) were able to restrict HIV-1 infection, however, viral cores in complex with
DUb-RhTRIM5α accumulated in the cytoplasm of infected cells, suggesting impaired
destabilization of cores in the absence of competent ubiquitination [171]. Importantly,
cells expressing a catalytically inactive version of the DUB, termed DUb*-RhTRIM5α,
maintained the ability to both restrict infection and destabilize viral cores [171]. We
previously observed the accumulation of DUb-RhTRIM5α-core complexes in the
cytoplasm of infected HeLa cells [171]. These findings were recapitulated in both THP-1
cells differentiated into macrophages and A549 cells (Fig 19-21). Importantly, from
these studies, it was unclear if the stabilized DUb-RhTRIM5α-capsid complexes were
being sequestered into autophagosomes for subsequent degradation.
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Figure 19. Co-localization of DUB-Fusion Proteins and HIV-1 p24 in THP-1 Cells.
THP-1 cells expressing the indicated Flag-tagged RhTRIM5 DUB fusion proteins were
differentiated into macrophages and infected with HIV-1. Colocalization between Flag
and HIV-1 p24 was assessed. Representative image are shown in (A), and a
magnification of a DUb-RhTRIM5α image is shown in (B).
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Figure 20.Co-localization of DUB-Fusion Proteins and HIV-1 p24 in A549 Cells.
A549 cells expressing the indicated Flag-tagged RhTRIM5 DUB fusion proteins infected
with HIV-1. Colocalization between Flag and HIV-1 p24 was assessed. Representative
image are shown in (A), and a magnification of a DUb-RhTRIM5α image is shown in
(B).
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Figure 21. Inhibition of the Ubiquitin Ligase Function of TRIM5α Stabilizes the
Association of RhTRIM5α with HIV-1 Viral Cores in THP-1 and A549 Cells. The
degree of colocalization of between the different TRIM5α fusion proteins (Flag-tagged)
and HIV-1 capsid (p24) at 6hpi in both THP-1 cells differentiated into macrophages and
A549 cells was measured. Error bars represent SEM of at least 20 images taken for
each cell line. Data are representative of three independent experiments. *** = p <
0.001 by one-way ANOVA.
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Generation of Deubiquitinase-Rhesus TRIMα Fusion Proteins
To more directly identify the specific determinants of how TRIM5α recruits
autophagic machinery and to determine if stabilized TRIM5α-viral core complexes are
recruited to autophagosomes, we generated a panel of fusion proteins in which the
catalytic domain of different deubiquitinase enzymes (DUBs), with different specificities
for polyubiquitinated linkages, was fused to the N-terminal RING domain of Rhesus
TRIM5α (Table 1). Our previous study utilized the HSV-1 UL36 deubiquitinating
enzyme, which has been reported to cleave both K48 and K63-linked polyubiquitin
chains [172, 188, 189]. The different deubiquitinase enzymes employed in the current
study were chosen for their ability to cleave only a single type of ubiquitin linkage, even
at high polyubiquitin concentrations in vitro [190]. In addition, each of these
deubiquitinase-RhTRIM5α fusions was paired with a catalytically inactive
deubiquitinase-RhTRIM5α fusion protein (denoted as "*") to control for the addition to
the N-terminus of RhTRIM5α due to the fusion protein [171-174, 191].

Table 1. Deubiquitinase (DUB)-RhTRIM5α Fusion Proteins Used in This Study. DUB enzymes were fused to the Nterminus of Rhesus TRIM5α, in frame between the Flag tag and the RING domain.
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Deubiquitinase-RhTRIM5α Fusion Proteins Restrict HIV-1 Infection
First, these deubiquitinase-RhTRIM5α fusions were screened for their ability to
restrict HIV-1 infection. A549 cells stably expressing each one of the DUB-RhTRIM5α
fusion proteins were infected with an HIV-1 reporter virus, in which infected cells appear
green. If ubiquitination is required for restriction, we would expect cells expressing one
of active DUBs to be permissive to infection by the reporter virus. However, in all cases,
both the catalytically active and inactive deubiquitinase fusion proteins retained the
ability to restrict HIV-1 infection (Fig 22). It is worth noting that the catalytically inactive
control for K48-specific DUB activity, OTUB1*-RhTRIM5α, was slightly more permissive
to infection compared to the other cell lines. We believe this activity is due to protein
folding changes that may have occurred due to the introduction of an alanine residue in
the catalytic site of the DUB enzyme. Nevertheless, as all the fusion proteins were able
to restrict HIV-1 infection, we concluded, from these data, that ubiquitination is not
required for the restriction of infection by RhTRIM5α.
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Figure 22. Deubiquitinase-RhTRIM5α Fusion Proteins Restrict HIV-1 Infection in
A549 Cells. RhTRIM5α fusion proteins were infected with a GFP reporter HIV-1 virus
and the proportion of infected cells (% GFP positive) was assessed 48hpi by flow
cytometry. Data are representative of two independent experiments.

K63-linked Ubiquitination Activity is Required for Restriction of Reverse
Transcription by TRIM5α
During restriction, TRIM5α is known to promote the disassembly of capsids prior
to the completion of reverse transcription, although this effect is abrogated in the
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presence of the proteasome inhibitor MG132 [156, 157]. To determine if the restriction
of reverse transcription requires ubiquitination activity, and to specifically define what
type of ubiquitin linkages are critical, we infected A549 cells expressing the DUBRhTRIM5α fusion proteins with an HIV-1 reporter virus and measured reverse
transcription products (Figure 23). As expected, we observed minimal production of
reverse transcription products in cells expressing RhTRIM5α, which is consistent with
previous reports [85, 155]. In contrast, we observed an accumulation of reverse
transcription products in cells expressing the catalytically active HSV-1 UL36
deubiquitinase fusion protein (DUb-RhTRIM5α). This enrichment is particularly evident
when comparing the active DUB to its catalytically inactive control, DUb*-RhTRIM5α
(Figure 23B). In this case, reverse transcription products did not accumulate, indicating
that ubiquitination activity by RhTRIM5α is necessary for its restriction of reverse
transcription.
Notably, the HSV-1 UL36 deubiquitinase enzyme demonstrates dual specificity to
cleave both K48- and K63-linked polyubiquitin chains [172, 188, 189]. To more precisely
define the ubiquitination linkages that are critical for the restriction of reverse
transcription by TRIM5α, we measured reverse transcription in cells expressing K63specific (AMSH-LP-RhTRIM5α) or K48-specific (OTUB1-RhTRIM5α) deubiquitinase
fusion proteins, along with their catalytically inactive controls. Significantly, we observed
an enrichment of reverse transcription products specifically in cells expressing the
catalytically active K63-specific deubiquitinase, AMSH-LP-RhTRIM5α, but not in cells
expressing the K48-specific DUB (Figure 23). Furthermore, this accumulation, once

72
again, is most apparent when comparing the active K63-specific DUB fusion to its
catalytically inactive control (Figure 23B). Importantly, we observed no difference in the
production of reverse transcription products in cells expressing the active or inactive
K48-specific DUB fusion proteins. From these data, we conclude that RhTRIM5α
requires K63-specific ubiquitination activity to restrict reverse transcription.
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Figure 23. K63-linked Ubiquitination Activity is Required for Restriction of
Reverse Transcription by TRIM5α. Deubiquitinase-RhTRIM5α fusion proteins were
infected with a GFP reporter HIV-1 virus and viral reverse transcription products were
measured by quantitative real time PCR. (A) Number of reverse transcription products
(late RT products) accumulating in the indicated cell lines. Error bars represent the
standard deviation of technical triplicates. Data are representative of at least three
independent experiments. (B) Values from (A) plotted as the ratio of active DUB to its
respective catalytically inactive control.

74
Inhibition of K63-linked Ubiquitination Produces Stable Association of RhTRIM5α
with HIV-1 Cores but Impaired Association with Autophagosome Membranes
Previous reports from our lab and others determined that TRIM5α cytoplasmic
bodies often colocalize with markers of autophagy, including p62/SQSTM1, LC3b, and
LAMP2A [146, 164, 181]. In addition, one study mapped the interactions necessary for
TRIM5α to bind to members of the mammalian ATG8 family, of which LC3b is a
member, and they identified a region in the Coiled-coil domain of TRIM5α that is
necessary for this interaction [146]. This was an intriguing finding, given that, as an E3
ubiquitin ligase, TRIM5α is autoubiquitinated, and the precise residues that are modified
in TRIM5α have been mapped to the RING domain [103]. We previously observed that
the ubiquitination activity of RhTRIM5α is required for its ability to destabilize viral
cores[171], and that in the absence of ubiquitination activity, RhTRIM5α forms stable
complexes with HIV-1 cores [171]. Therefore, we sought to determine if ubiquitination,
and to define what type of ubiquitin linkage, is required for the stable association of
TRIM5α with HIV-1 and for the recruitment of autophagic machinery to TRIM5α. To this
end, we generated A549 cell lines stably expressing both YFP-tagged LC3b (YFP-LC3)
and each one of the deubiquitinase-RhTRIM5α fusions. YFP-LC3 was utilized to mark
autophagosome formation. LC3, a diffusely expressed cytoplasmic protein, binds to
nascent autophagosome membranes, and therefore, punctate LC3 signal serves as
marker of autophagosome formation. Following infection with HIV-1, we measured the
degree of colocalization between the RhTRIM5α fusion proteins, HIV-1 p24 capsid
protein, and/or YFP-LC3 (Figure 24-25).
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Consistent with previous reports, we observed minimal stable association
between RhTRIM5α and HIV-1 p24, as RhTRIM5α rapidly destabilizes viral cores
(Figure 24-25). However, when K63-linked ubiquitination by RhTRIM5α is inhibited, as
in the case of cells expressing DUb-RhTRIM5α and AMSH-LP-TRIM5α, we observed
significant stable co-localization between TRIM5α the viral core, particularly when
comparing these DUBs to their catalytically inactive controls (Figure 24-25). Importantly,
we measured minimal stable co-localization between the K48-specific DUB fusion
protein (OTUB1-RhTRIM5α) and HIV-1 p24, and critically there was no significant
difference between the catalytically active and inactive fusions (Figure 25A).
Conversely, we observed that K63-liked ubiquitination is critical for the association of
RhTRIM5α with YFP-LC3, as both DUb-RhTRIM5α and AMSH-LP-TRIM5α showed
minimal co-localization with LC3, in contrast to their catalytically inactive counterparts
(Figure 25B). Collectively, these data indicate that the inhibition of K63-linked
ubiquitination produces a stable association between RhTRIM5α and HIV-1 cores, and
that K63-linked ubiquitination activity is critical for the association of TRIM5α with the
autophagosome membrane marker LC3. Notably, there was minimal triple
colocalization between the RhTRIM5α, LC3, and p24, suggesting that autophagic
machinery is not recruited to the sites of core disassembly.
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Figure 24. Colocalization of DUB-Fusion Proteins, HIV-1 p24, and/or YFP-LC3 in
A549 Cells. Representative images of A549 cells expressing the indicated Flag-tagged
RhTRIM5α DUB fusion proteins infected with HIV-1. Colocalization between Flag, HIV-1
p24, and/or YFP-LC3 was assessed (see Figure 24).
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Figure 25. Inhibition of K63-linked Ubiquitination Produces Stable Association of
RhTRIM5α with HIV-1 Cores but Impaired Association with Autophagosome
Membranes. A549 cells expressing deubiquitinase-RhTRIM5α fusion proteins and
YFP-LC3 were infected with HIV-1. The degree of colocalization of between the
different TRIM5α fusion proteins (Flag-tagged) and the HIV-1 capsid (p24) (A), or YFPLC3 (B) was measured. Error bars represent SEM of at least 20 images taken for each
cell line. Data are representative of three independent experiments. *** = p < 0.001, ** =
p < 0.01 by one-way ANOVA.
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p62 is Critical for TRIM5α Association with Autophagosome Membranes
p62/SQSTM1 is an autophagic adaptor protein that can bind ubiquitinated substrates
and direct them to autophagosomes [192]. We previously determined that p62
colocalizes with TRIM5α cytoplasmic bodies [164]. To determine if p62 is required for
the association of TRIM5α with autophagosomes, we utilized CRISPR/Cas9 genome
editing to target p62 or a non-targeting gRNA in A549 cells stably expressing YFP-LC3.
These cells were subsequently transduced to stably express either RhTRIM5α or DUb*RhTRIM5α, given that this was the fusion protein that most potently colocalized with
YFP-LC3 (Figure 26). We quantified the association between RhTRIM5α and LC3 and
observed that, in the absence of p62, there is significantly less colocalization between
YFP-LC3 and RhTRIM5α, indicating that p62 is a critical mediator of the interaction
between RhTRIM5α and autophagosomes (Fig 26).

79

Figure 26. p62 is Critical for TRIM5α Association with Autophagosome
Membranes. A549 cells were depleted of p62 via CRISPR/Cas9 genome editing.
These cells were subsequently transduced to express YFP-LC3 and the indicated DUB
constructs (A). (B) Following infection with an HIV-1 reporter virus, the degree of
colocalization of between the different TRIM5α fusion proteins (Flag-tagged) and YFPLC3 was measured. Error bars represent SEM of at least 20 images taken for each cell
line. Data are representative of three independent experiments. *** = p < 0.001, * = p <
0.05 by Student’s t-test.

CHAPTER FIVE
DISCUSSION
Summary of data
TRIM5α, as other TRIM proteins, has been shown to associate with markers of
the autophagy pathway [146, 164, 181-184], and given TRIM5α’s role as a retroviral
restriction factor, that this association suggests a functional relationship between the
autophagy pathway and TRIM5α. The goal of these studies was to examine the
contributions of ubiquitination and association with autophagic effectors to TRIM5α’s
anti-retroviral functions.
First, we identified that the subcellular distribution of YFP-RhTRIM5α changes in
the presence of BafA1 and MG132, with the accumulation of more cytoplasmic bodies
of YFP-RhTRIM5α observed in the presence of autophagy inhibition compared to
proteasome inhibition (Figure 13). We also determined that the YFP-RhTRIM5α
cytoplasmic bodies colocalize with markers of the autophagy pathway (Figure 14).
These observations provided the rationale to examine the role, if any, that autophagy
plays in the restriction of retroviruses by TRIM5 proteins. For our study, we selected two
important macroautophagy factors, Beclin1 and ATG5, which are critical for the
nucleation and elongation of autophagosome membranes. It is worth noting that
autophagy is a very complex cellular process involving many cellular proteins, and it is
possible that in some cases, there may be redundant proteins that have similar effects.
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Importantly, however, Beclin1 appears to be essential for macroautophagy [193] and
thus was a valuable target for our assessment of autophagy in the functions of TRIM5α.
We observed that retroviral restriction was not impacted by depletion of
autophagic mediators by siRNA (Figure 15). This was true in the case of endogenously
expressed huTRIM5α, which still mediated potent inhibition of N-MLV infection and
reverse trancription following ATG5, Beclin1 or p62 knockdown. However, these studies
do not exclude the possibility that small amounts of these mediators remaining after
siRNA knockdown are sufficient to preserve TRIM5α-mediated restriction. We therefore
used the CRISPR-Cas9 genome editing system to deplete cells of ATG5 or Beclin1 and
similarly assessed N-MLV restriction by huTRIM5α (Figure 16). Similar to our
knockdown studies (Figure 15) no relief in retroviral restriction was observed (Figure
16D and F) in cells depleted of ATG5 or Beclin1. In addition, restriction of viral reverse
transcription was intact following ATG5 and Beclin1 knockout (Figure 16G and H).
Although we cannot discount the possibility that cells depleted of ATG5 or Beclin1 may
possess alternative mechanisms of substrate degradation via autophagy, these results
collectively demonstrate that restriction of retroviral infection and reverse transcription
by TRIM5α is independent of ATG5 and Beclin1.
We obtained similar results when restriction of HIV-1 by RhTRIM5α (Figure 17)
or TRIM-Cyp (Figure 18) was examined. Restriction of HIV-1 was not impacted by
ATG5 or Beclin1 deletion (Figure 17). We did observe that ATG5 depletion caused a
decrease HIV-1 infection (Figure 17B), although HIV-1 restriction remained intact in
these cells (Figure 17B). These data are in apparent contrast to the findings from a
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recent study, which observed that the depletion of autophagic adaptor proteins
abrogated RhTRIM5α-mediated restriction of HIV-1 [146]. One noticeable difference
between our studies was that the Mandell et. al. study utilized primary Rhesus
fibroblasts to examine the role of autophagic adaptors in the restriction mechanism of
RhTRIM5α; they observed modest restriction of HIV-1 by the primary Rhesus
fibroblasts, with minimal relief of restriction observed following the depletion of
rhTRIM5α by siRNA [146]. Our study dissected the role of autophagy in retroviral
restriction in the context of much more potent restriction, as observed in the restriction
of N-MLV by huTRIM5α and HIV-1 by RhTRIM5α or TRIM-Cyp. Thus, we suspect that
the differences between our results and the Mandell et. al. study stem from the more
pronounced degree of restriction observed in our studies. However, we cannot exclude
the possibility that cell type or species specific differences explain the apparent
discordance between our observations. Furthermore, it should be noted that the
Mandell et. al. study assessed infectivity by measuring the amount of HIV-1 p24 protein
in the cellular lysate of infected cells, rather than through the more conventional
approach of measuring the expression of a reporter gene expressed upon viral
integration. In this regard, autophagy has been implicated in regulating virus production
[194], and therefore, the quantification of p24 in the cellular lysate, which could
represent CA associated with the core or unincorporated CA monomers, does not
directly reflect the restriction capabilities of TRIM5α and its relationship to autophagy.
Although we concluded that autophagy is not required for retroviral restriction by
TRIM5α proteins, it is possible that the association of TRIM5α proteins with autophagy
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markers could have some other role in TRIM5α’s function. In the present study, we
assessed the role of the ubiquitin ligase activity of RhTRIM5α on its restriction of HIV-1
infection, reverse transcription, stable association with viral capsids, and recruitment
with the autophagosome marker LC3. We conclude that K63-linked ubiquitin ligase
activity of RhTRIM5α is critical for its restriction of reverse transcription and association
with LC3. In the absence of K63-linked ubiquitination, we observed a restoration of HIV1 reverse transcription and the formation of stable complexes of RhTRIM5α and HIV-1.
Finally K63-linked ubiquitination is critical for RhTRIM5α’s association with LC3. The
results from our study are in agreement with a recent report which identified that
TRIM5α is modified by K63-linked ubiquitination in vitro [103]. Furthermore, the same
study assessed the contribution of ubiquitination to the restriction of reverse
transcription by TRIM5α and found that the restriction of reverse transcription by
TRIM5α was relieved in cells expressing a K63R mutant ubiquitin, in which the
formation of K63-linked polyubiquitin chains is blocked [103]. One pitfall of such an
approach is that K63-linked ubiquitination is likely important for many cellular processes,
and expression of this ubiquitin mutant could alter cellular pathways that could have an
indirect impact on the restriction functions of TRIM5α. Our approach, in which we fused
different deubiquitinases to RhTRIM5α, offered the opportunity to study ubiquitination in
the context of the assembly of TRIM5α around a capsid, as this assembly has been
shown to be critical to the activation of the E3 ligase function of TRIM5α [102].
Furthermore, by pairing each DUB with a catalytically inactive control protein, we were
able to focus our analysis on the phenotypes associated with the enzymatic activity of
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the DUB, rather than changes that could be a consequence of adding a fusion to the Nterminus of Rhesus TRIM5α. Finally, by including DUB enzymes with unique
specificities for cleaving K48 or K63-linked polyubiquitin linkages, we demonstrated that
the ubiquitin-dependent steps in restriction by TRIM5α specifically require its ability to
generate K63-linked polyubiquitin chains. We are currently confirming the
deubiquitinase activity of the each of the DUB-fusion proteins in in vitro studies.
Implications of the Data: TRIM5α and the Autophagy Pathway
Two recent studies have considered the importance of the autophagy pathway in
facilitating core disruption by TRIM5α [146, 165]. This hypothesis is particularly
attractive, given how K63-linked ubiquitin chains have been associated with the
recruitment of autophagy machinery in cells [195]. In this model, TRIM5α binds to and
forms an assembly around incoming viral cores, synthesizes K63-linked polyubiquitin
chains [102], and recruits autophagic machinery to degrade both TRIM5α itself and its
bound viral core [146, 165]. We showed that K63-linked ubiquitination is required for
TRIM5α’s association with autophagosome membranes (Figure 25) and its ability to
restrict viral reverse transcription (Figure 23). A hypothesis one can draw from these
data is that in the absence of K63-linked ubiquitination, TRIM5α is unable to recruit
autophagic machinery; as result, stable complexes of TRIM5α bound to the core persist
in the cytoplasm (Figure 24-25), allowing sufficient time for reverse transcription to
proceed. In this case, the association with autophagosomes would be essential for the
ability of TRIM5α to inhibit reverse transcription. However, we determined that the
depletion of key macroautophagy factors ATG5 or Beclin1 had no impact on the ability

85
of TRIM5α to restrict reverse transcription [181]. These finding are in opposition to
recent work highlighting the central role of specifically these two factors, along with p62,
in restriction by TRIM5α [146]. While we disagree with this finding, it is possible that
TRIM5α’s association with the autophagy pathway may be relevant in other contexts.
Specifically, one recent study reported that HIV-1 infection is suppressed in
Langerhans cells, a subset of dendritic cells found within mucosal tissues, and this
restriction is mediated by TRIM5α [165]. In their model, Langerhans cells bind HIV-1 via
the C-type lectin receptor Langerin, which in turn facilitates the binding of TRIM5α to the
internalized virus [165]. Subsequently, TRIM5α directs the core complex to the
autophagy pathway for degradation [165]. Importantly, this study found that this
particular pathway of TRIM5α-mediated restriction was specific to Langerhans cells, as
dendritic cells expressing a different C-type lectin receptor, DC-SIGN, were unable to
direct the TRIM5α-virus complex to autophagosomes for degradation [165]. However,
our studies investigating the role of autophagy in restriction determined that restriction
of infection by different TRIM5 proteins occurred in the absence of ATG5 or Beclin1
(Figures 15-18) or K63-linked ubiquitination, which is critical for the association of
TRIM5α with autophagosome membranes (Figure 22). This is supported by biochemical
experiments which observed the spontaneous formation of TRIM5α assemblies on in
vitro assembled capsid assemblies (Figure 8). Taken together, it is difficult to conceive
how the formation of such an assembly, or the restriction to infection this assembly
seems to confer, would be different in the context of Langerhans cells. However, a
possible explanation for this apparent discord may be related to the ability of TRIM5α to
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promote the induction of an innate signaling response upon capsid recognition [35,
102]. In this regard, it is possible that TRIM5α signaling may occur without the formation
of a full, restricting TRIM5α assembly around the viral core, and it is possible that, in
Langerhans cells, induction of this innate signaling response is sufficient to suppress
infection and could explain the decreased infection in this cell type observed by Ribeiro
and colleagues.
Nonetheless, identifying a restriction mechanism within Langerhans cells is
particularly important, given their prevalence in mucosal sites, as these sites are the
major route of transmission of HIV-1. It is also possible that the association of TRIM5α
with autophagosomes might be more relevant for the generation of adaptive immune
responses to the virus. In this case, autophagosomes containing TRIM5α-virus
complexes could be fused with MHC class II containing compartments, thereby
facilitating the delivery of antigens to MHC class II for presentation [196]. Therefore,
association of TRIM5α with autophagosomes, in the context of infection, could be a
means of bridging the innate and adaptive immune responses and should be an avenue
of future investigation.
Implications of the Data: TRIM5α and the Proteasome
Previous reports determined that the destabilization of retroviral capsids by
TRIM5 proteins is sensitive to proteasome inhibitors [156-158], and one implication of
these observations is that TRIM5α utilizes proteasome machinery to destabilize
retroviral capsids. However, this model raises important questions. Proteasomal
degradation is generally associated with K48-linked rather than K63-linked polyubiquitin
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linkages [126-128, 132-134]. It is possible that TRIM5α, which produces K63-linked
polyubiquitin chains exclusively ([103] and the current study), recruits proteasomal
machinery through a noncanonical mechanism. Two studies determined that while both
K48- and K63-linked polyubiquitin linkages can bind to proteasomal components in vitro
[135, 138], the processivity with which the proteasome unfolds substrates is
dramatically reduced in substrates bearing K63-linked chains, compared to K48-linked
chains [134]. Furthermore, individual TRIM5α proteins bind to the capsid with low
affinity [114], and therefore, it is unclear how this low affinity interaction, coupled with
the low processivity associated with K63-linked polyubiquitin chains, explains the
efficient destabilization of the core that is observed during retroviral restriction by
TRIM5α. Finally, many of the early studies investigating the role of the proteasome in
restriction utilized proteasome inhibitors, such as MG132. However, several studies
determined that treatment of cells with MG132 resulted in an accumulation of proteins
bearing ubiquitin linkages of all types except for K63-linkages [142, 186], strongly
suggesting that substrates marked with K63-linked polyubiquitin are not destined for
proteasomal degradation. Collectively, these observations justify a reevaluation of the
role of the proteasome in restriction by TRIM5α.
It is worth considering how our studies with the DUB-RhTRIM5α fusion proteins,
which essentially recapitulated the effects of MG132 observed in earlier studies [156,
157], did so without, ostensibly, modulating the proteasome. One explanation to
reconcile these two effects is that treatment with MG132 is known to deplete the cellular
pool of free ubiquitin [197]. This, in turn, could potentially limit the availability of free
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ubiquitin available for TRIM5α to complete its ubiquitin-dependent steps during
restriction. Therefore, the effects of MG132 on restriction are likely phenotypes
associated with side-effects of the drug itself rather than a disruption of a proteasomedependent step in restriction.
The data from the current study support a model, first set forth by Barbie GanserPornillos et. al., in which the formation of an assembly of TRIM5α around a retroviral
core is sufficient to block infection [115]. Autophagic machinery is not required for the
restriction of retroviral infection, as both ATG5 or Beclin1 knockout cells maintained
potent restriction of multiple retrovirsues (Figure 15-18). Furthermore, cells expressing a
RhTRIM5α fusion protein in which K63-linked ubiquitnation is inhibited maintain potent
restriction of HIV-1 infection (see AMSH-LP-RhTRIM5α, Figure 22) despite minimal
association with the autophagosome membrane marker LC3 (Figure 25). Importantly,
core destabilization, which occurs prior to reverse transcription [155] and requires the
K63-specific ubiquitin ligase activity of TRIM5α (Figure 25) does not appear to be
required for the restriction of infection. This suggests that TRIM5α likely evolved
multiple mechanisms of restricting retroviral infection. An early block, which requires the
E3 ligase activity on the RING domain of TRIM5α, promotes the destabilization of cores
prior to the completion of reverse transcription. However, infection is still blocked
without the E3 ligase activity, suggesting a later block to infection. This later block is
remarkably similar to the mechanism of restriction of murine Fv1, the first characterized
retroviral restriction factor.

Figure 27. Current Perspective of the Mechanism of Retroviral Restriction by TRIM5α. (left panel) During infection,
retroviruses reverse transcribe their RNA genome (pink) into DNA (green), uncoat their capsid (blue) and traffic to the
nucleus for integration. (right panel) TRIM5α [6] exists as diffuse protein and cytoplasmic bodies. K63-specific ubiquitin
ligase activity of TRIM5α is critical for its association with autophagosome membrane markers and its ability to destabilize
viral cores prior to the completion of reverse transcription. In the absence of K63-specific ubiquitin ligase activity, TRIM5α
forms a stable association with the capsid, allowing reverse transcription to proceed, however infection is still blocked.
This favors a model whereby the formation of a TRIM5α assembly around a capsid is sufficient to inhibit infection, while
ubiquitin ligase activity of TRIM5α is needed to inhibit reverse transcriptio
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Fv1 inhibits retroviral infection after reverse transcription but before integration, a
phenotype mirrored in RhTRIM5α fusions with incompetent K63-linked ubiquitin ligase
activity (AMSH-LP-RhTRIM5α, Figure 22-23). Importantly, although TRIM5α and Fv1
are very different at the primary sequence level, they each likely evolved independently
in response to retroviral challenge over time [86, 198]. However, the evolution of the
RING domain in TRIM5α proteins likely afforded TRIM5α the capacity to effectively and
efficiently block both retroviral reverse transcription and infection.
Intriguingly, TRIM5-based capsid binding restriction factors have evolved at least
twice, independently, through the retrotransposition of a Cyclophilin A pseudogene to
replace the SPRY domain of TRIM5α [199-203]. While this retrotranspostion event
could have occurred by chance, it is possible that the fusion of a capsid binding factor,
such as cyclophilin A, to the TRIM motif conferred some selective advantage against
retroviral pathogens, hence their independent evolution among different primates. In this
regard, in a laboratory setting, fusion of cyclophilin A to a protein that is known to
multimerize generates a capsid-binding factor that is competent to restrict HIV-1
infection [99]. If multimerization was the only requirement to generate an efficient
capsid-binding restriction factor, why would TRIM-based factors, specifically, arise
repeatedly? One hypothesis is that in addition to multimerization, the TRIM motif, and
specifically the RING domain, confers the ability to generate an antiviral signaling
response [35], and thus was selected for over time, given the evolutionary advantages
associated with the expression of sensors for pathogens.Upon binding to a restrictionsensitive capsid, the ubiquitin ligase activity of TRIM5α is activated [102], and in turn
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TRIM5α has been shown to generate free, unanchored K63-linked polyubiquitin chains
[35]. These ubiquitin chains can subsequently bind to and promote the activation of the
cytoplasmic kinase TAK1, which in turn promotes the activation and upregulation of AP1 and NFκB-dependent genes [35]. Finally, the anti-retroviral activity of TRIM5α begins
with its binding to the retroviral capsid, and because the capsid is considered
“genetically fragile” and is required for many aspects of the retroviral life cycle [27, 36,
37], it is unlikely to evolve to avoid TRIM5α binding. Therefore, TRIM5α has the ability
to efficiently couple its restriction function with the generation of an innate immune
response, and studies to define the underlying mechanisms of restriction can help to
enhance the activity of human TRIM5α against significant pathogens like HIV-1.
Future Directions
This work leaves a few important lingering questions. First, it is worth revisiting if
proteasomes are indeed involved in the core destabilization function of TRIM5α. This
work suggests that this destabilization occurs independently of proteasomes and
supports a model whereby the destabilization of capsids may occur as a result of the
dynamic movement of individual SPRY domains bound to the capsid [100]. In this
model, the spring-like movement of the L2 region (Figure 7), which exists as a helix,
could displace individual SPRY domains bound to the capsid and promote capsid
disassembly [100]. However, within this model, it is unclear what role TRIM5α’s E3
ligase activity plays, although from the current work it is clear that this ligase activity is
required for capsid disassembly. It is possible that as the activation of the E3 ligase
function promotes the ubiquitination of TRIM5α, this in turn imparts some
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conformational change in the protein that facilitates the dynamic movement of the L2
spring, and subsequently, displacement of the SPRY domain bound to the capsid. In
another model, a recent study described how a cytoplasmic polyanion, IP 6, binds to and
stabilizes HIV-1 cores, in a manner that the authors suggest prevents spontaneous
disassembly of the cores [204]. In this case, ubiquitination of TRIM5α bound to a capsid
could promote the displacement of IP6 and summarily, induce the disassembly of the
capsid.
Furthermore, early studies describing proteasome-dependent steps in TRIM5αmediated restriction relied on MG132 [156-158, 162]. For example one study reported
that during restriction, viral core components such as the RNA genome, reverse
transcriptase and integrase proteins, and the capsid itself, are likely degraded by the
proteasome [158]. However, given that the same study could identify no direct
ubiquitination of core components [158], and the caveats associated with the model of
proteasome-dependent destabilization described above, it is unclear what role, if any,
the proteasome has in TRIM5α’s restriction functions.
Finally it is important to consider the implications of this work on the development
of strategies to improve the activity of human TRIM5α against HIV-1. While human
TRIM5α is not as potent as Rhesus TRIM5α in blocking HIV-1 infection, several lines of
evidence suggest that there are opportunities to improve its functions. For example,
several reports have characterized SNPs in human TRIM5α that are associated with
higher viral loads and a more rapid progression towards AIDS [205-207], suggesting
that wild-type human TRIM5α is exerting some protective effect that is absent in
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individuals bearing these SNPs. Furthermore, a recent study described how an
artificially stabilized version of human TRIM5α had the ability to restrict HIV-1 infection
to a degree comparable to that performed by Rhesus TRIM5α [208]. In this vein,
strategies that promote the stabilization of human TRIM5α may enhance its anti-HIV-1
activity. As a proof of this principle, it would be interesting to assess whether human
TRIM5α fused to the K63-specific deubiquitinase enzyme, which we showed produces a
stable complex between AMSH-LP-RhTRIM5α and HIV-1 (Figures 24-25), could impart
improved restriction capabilities to human TRIM5α.
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